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The mammalian 26S proteasome is a 2500 kDa multi-catalytic
complex involved in intracellular protein degradation. We
describe the synthesis and properties of a novel series of non-
covalent di-peptide inhibitors of the proteasome used on a capped
tri-peptide that was ﬁrst identiﬁed by high-throughput screening
of a library of approx. 350000 compounds for inhibitors of
the ubiquitin–proteasome system in cells. We show that these
compounds are entirely selective for the β5 (chymotrypsin-like)
site over the β1 (caspase-like) and β2 (trypsin-like) sites of
the 20S core particle of the proteasome, and over a panel of
less closely related proteases. Compound optimization, guided
by X-ray crystallography of the liganded 20S core particle,
conﬁrmed their non-covalent binding mode and provided a
structural basis for their enhanced in vitro and cellular potencies.
We demonstrate that such compounds show low nanomolar
IC50 values for the human 20S β5 site in vitro,a n dt h a t
pharmacological inhibition of this site in cells is sufﬁcient to
potently inhibit the degradation of a tetra-ubiquitin–luciferase
reporter, activation of NFκB (nuclear factor κB) in response
to TNF-α (tumour necrosis factor-α) and the proliferation of
cancer cells. Finally, we identiﬁed capped di-peptides that show
differential selectivity for the β5 site of the constitutively
expressed proteasome and immunoproteasome in vitro and in
B-cell lymphomas. Collectively, these studies describe the syn-
thesis, activity and binding mode of a new series of non-covalent
proteasomeinhibitorswithunprecedentedpotencyandselectivity
for the β5 site, and which can discriminate between the con-
stitutive proteasome and immunoproteasome in vitro and in cells.
Key words: chymotrypsin-like, immunoproteasome, 26S protea-
some, proteasome inhibitor, β5-subunit, ubiquitin–proteasome
system (UPS).
INTRODUCTION
The 26S proteasome is a very large (2500 kDa) multi-
subunit proteolytic complex found in high abundance in all
eukaryotic cells that is responsible for the regulated degradation
of the majority of intracellular proteins, including those
involved in signal transduction, cell-cycle control, apoptosis and
inﬂammatory responses [1–6]. It is composed of the 20S catalytic
core particle that is capped at one or both ends by the 19S
regulatory complex, also called PA700 [1–6]. The 20S core
particle is comprises four stacked heteroheptameric rings that
form a cylindrical structure with 2-fold axial symmetry. The
two outer α rings gate substrate entry through their interaction
with the 19S regulatory complex, which itself serves to bind,
unfold, de-ubiquitinate and translocate into the catalytic core
substrate proteins that have been conjugated to poly-ubiquitin
[1–6]. The two inner β rings form the central proteolytic
chamber and each contain three active sites with distinct substrate
speciﬁcities. These are located on the β1, β2a n dβ5 subunits
and are referred to as having caspase-like, trypsin-like and
chymotrypsin-like activities on the basis of their preference for
cleaving peptides after acidic, basic or hydrophobic amino acid
residuesrespectively[1–6].Asecondformofthe20Sproteasome
termed the immunoproteasome exists in cells of lymphoid origin
and can be induced in most, if not all, cells in response to
the pro-inﬂammatory cytokine interferon-γ [5–7]. This enzyme
contains distinct catalytic subunits, designated β1i, β2i and
β5i, and is primarily involved in the generation of antigenic
peptides for MHC class I presentation, although a function for
the immunoproteasome in cytokine production has also been
described [8].
For each of the 20S catalytic β-subunits, the hydroxy
group of the N-terminal threonine residue (Thr
1Oγ)s e r v e sa s
the nucleophile that initiates cleavage of the peptide bond
[4,5,9]. Various natural and synthetic compounds that contain
electrophilic centres or ‘warheads’ inhibit the proteasome by
formingcovalentadductswiththeseactive-sitethreonineresidues,
including peptide aldehydes, vinyl sulfones, boronic acids,
α
 β
 -epoxyketones, 2-keto-1,3,4-oxadiazoles and β-lactones
(Figure 1A) [4–6,9–11]. The di-peptide boronic acid bortezomib
(PS-341 or VELCADE®, Millennium Pharmaceuticals, Inc.)
is among the most potent, stable and selective of these
inhibitors [12–15], and shows nanomolar potency with respect
to cytotoxicity across a broad range of human tumour cell types
in vitro [13,14]. It is in clinical use for the treatment of multiple
myeloma [16–19] and refractory mantle cell lymphoma [20],
Abbreviations used: Ac, acetyl; AMC, 7-amino-4-methylcoumarin; Boc, t-butoxycarbonyl; HBTU, O-benzotriazole-N,N,N ,N -tetramethyluronium
hexaﬂuorophosphate; HEK, human embryonic kidney; LC50, half-maximal lethal concentration; MPD, 2-methyl-2,4-pentanediol; NFκB, nuclear factor
κB; IκB, inhibitory protein of NFκB; NFκB-Luc, NFκB–luciferase; PA, proteasomal activator; PDL, poly-D-lysine; RNAi, RNA interference; siRNA, small
interfering RNA; Suc, succinyl; TEV, tobacco etch virus; TNF-α, tumour necrosis factor-α; 4xUb-Luc, tetra-ubiquitin–luciferase; UPS, ubiquitin–proteasome
system; Z, benzyloxycarbonyl.
1 Present address: Epizyme, Inc., 840 Memorial Drive, Cambridge, MA 02139, U.S.A.
2 To whom correspondence should be addressed (e-mail jonathan.blank@mpi.com).
The structural co-ordinates of the yeast 20S proteasome with the indicated ligand bound reported will appear in the PDB under accession codes: 3MG0
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Figure 1 Examples of covalent (A) and non-covalent (B) proteasome inhibitors
and is being evaluated for the treatment of other malignancies
[21–23]. Bortezomib induces cell death through a variety of
transcriptional, translational and post-translational mechanisms,
and may be preferentially cytotoxic to cancer cells by enhancing
endoplasmic reticulum stress, increasing the expression of pro-
apoptotic factors and/or inhibiting pro-survival or DNA-damage
repair pathways [4–6,21–23]. More recently, two further closely
relateddi-peptideboronicacids,CEP-18870andMLN9708,have
been described that inhibit cancer cell proliferation in vitro and
show anti-tumour activity in solid and haematological preclinical
tumour models [24,25].
Bortezomib binds with very high afﬁnity to the β5 site of
the proteasome, and to a lesser extent the β1a n dβ2 sites
[15], and behaves as a slowly reversible inhibitor (t1/2∼110 min
for dissociation from the β5 site [25]). Analysis of the crystal
structure of the yeast 20S in complex with bortezomib indicates
that the highafﬁnity of the drugis partly mediated by the covalent
interaction of the boron atom with the nucleophilic oxygen of
Thr
1Oγ, and by the hydrogen bonding between the two acidic
boronate hydroxy groups and the amine groups of Gly
47N and
Thr
1N within each active site [5,9,26]. These properties are likely
to contribute to the effectiveness of bortezomib as an anti-cancer
agent for the treatment of haematological malignancies, but may
limit its distribution and therefore broader utility in solid tumours
due to the high tissue abundance of the target (the proteasome has
beenestimatedtocomprise2%oftotalcellularprotein[6]).More
recently, the β-lactone salinosporamide A (NPI-0052) [27] and
the epoxyketone carﬁlzomib (PR-171) (Figure 1A) [28], which
are analogues of lactacystin and epoxomicin respectively, have
demonstrated activity in preclinical models of multiple myeloma
and chronic lymphocytic leukaemia, and have entered clinical
trials for advanced solid and haematological malignancies [23].
Thesecovalentinhibitorshavecomparablepotencytobortezomib,
butdifferinthattheyformessentiallyirreversibleadductswiththe
active site Thr
1Oγ residues of the proteasome [4,5,9,10,15,27–30].
Although the reactive ‘warheads’ of covalent proteasome
inhibitors can contribute to enzyme potency, they can also lack
speciﬁcity and be excessively reactive and unstable [10,11,15],
properties which may limit their efﬁcacy in vivo. Non-covalent
inhibitors that are readily reversible in their interactions with
the catalytic 20S β-subunits provide an alternative mechanism
for proteasome inhibition. Such inhibitors may offer therapeutic
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advantages by enabling more widespread tissue distribution
through their more rapid binding and dissociation kinetics.
TMC-95A is a complex natural cyclic tri-peptide (Figure 1B)
that competitively and non-covalently inhibits the chymotrypsin-
like activity of the proteasome with nanomolar potency, and
also inhibits the caspase-like and trypsin-like activities at higher
concentrations [4,5,9,10,31]. The high afﬁnity of TMC-95A
is due to its rigid heterocyclic ring system, which provides
speciﬁchydrogen-bondinginteractionswithineach20Sactivesite
without covalent modiﬁcation of the catalytic threonine residues
[4,5,9,32]. In addition, synthetic analogues of TMC-95A have
been described, including endocyclic biphenyl-ether macrocyles
and non-constrained linear tri-peptides that bind non-covalently
withalteredafﬁnitiesforthetrypsin-andcaspase-likesitesrelative
to the chymotrypsin-like site [5,9,33,34]. TMC-95A shows cyto-
toxicity in the low micromolar range in cancer cells, although the
mechanism-based effects of TMC-95A or its derivatives have not
been demonstrated [4]. Other non-covalent proteasome inhibitors
include a series of 5-methoxy-1-indanone di-peptide benzamides
(e.g. CVT-659) [35,36] and 2-aminobenzylstatine derivatives
(Figure1B)[37]thatselectivelyinhibitthechymotrypsin-likesite
with submicromolar potencies, although these compounds also
have poor cellular activity. However, homology modelling of a
2-aminobenzylstatine compound in the chymotrypsin-like
binding pocket of the proteasome has led to the design a
non-covalent tri-methoxy-L-phenylalanine-containing tri-peptide
with maintained selectivity and greatly increased cell potency
(Figure 1B) [38]. This compound is the most potent non-
covalent proteasome inhibitor described to date, inhibiting the
chymotrypsin-like activity in MDA-MB-435 cells and their
proliferation with IC50 values of 20 nM and 60 nM respectively
[38].
In an effort to identify cell-active inhibitors of the UPS
(ubiquitin–proteasome system) with novel chemical scaffolds,
we have screened a library of approx. 350000 compounds
using a cell-based assay that monitors accumulation of a
4xUb-Luc (tetra-ubiquitin–luciferase) reporter in response to
proteasome inhibition [15,39]. Using this approach, we report
the identiﬁcation of a C- and N-terminally capped tri-peptide
derivedfromtheunnaturalaminoacidS-homo-phenylalaninethat
potently and selectively inhibits the chymotrypsin-like activity of
themammalian andyeast20Sproteasomes.Furtheroptimization,
guided by X-ray crystallography of compounds in complex with
puriﬁed yeast 20S, has yielded a series of non-covalent di-
peptide inhibitors of the proteasome with unprecedented in vitro
and cellular potencies. The synthesis, binding mode and cellular
activity of these compounds are described in the present study.
EXPERIMENTAL
Cell culture
Cells were from the A.T.C.C. (Manassas, VA, U.S.A.), with the
exception of the diffuse large B-cell lymphoma lines which were
obtained from the following sources: Karpas-1106P, Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ;
Braunschweig, Germany); WSU-DLCL2, Asterand (Detroit, MI,
U.S.A.);andOCI-Ly10,providedbyDrLouisM.Staudt(National
Cancer Institute, National Institutes of Health, Bethesda, MD,
U.S.A.). Cells were cultured at 37◦C in a humidiﬁed air/6%
CO2 atmosphereinmediumsupplementedwith10%fetalbovine
serum, except for the medium for Karpas-1106P and OCI-Ly10
cells which contained 20% fetal bovine serum, and 100 units/ml
penicillin/100 μg/ml streptomycin (all from Invitrogen), as
speciﬁed: Calu6 cells, minimum essential medium; H460, WSU-
DLCL2 and Karpas-1106P cells, RPMI 1640 medium; HCT116
and HT29 cells, McCoy’s 5a medium; and OCI-Ly-10, Iscove’s
modiﬁed Dulbecco’s medium. Clonally-derived stable MDA-
MB-231 cells expressing four tandem copies of ubiquitin fused
to ﬁreﬂy luciferase (4xUb-Luc) and HEK (human embryonic
kidney)-293 cells expressing NFκB-Luc [NFκB (nuclear factor
κB)–luciferase] were generated and maintained as described
previously [15].
Reporter assays
Cells were seeded at 10000 cells per well in white BioCoat
TM
PDL (poly-D-lysine)-coated 384-well plates (BD Biosciences) at
16–24 h prior to compound treatment. For the 4xUb-Luc assays,
MDA-MB-231 cells were incubated with compound for 8 h.
For NFκB-Luc assays, HEK-293 cells were pre-treated for 1 h
with proteasome inhibitor and then stimulated with 10 ng/ml
recombinant human TNF-α (tumour necrosis factor-α)( R & D
Systems) for a further 3 h in the continued presence of the
compound. Fireﬂy luciferase activity was measured using Bright-
Glo
TM reagents according to the manufacturer’s instructions
(Promega) in a LEADseeker
TM plate reader (GE Healthcare Life
Sciences).InhibitionofNFκB-Lucactivitywascalculatedrelative
to a no-compound (DMSO) control, whereas 4xUb-Luc reporter
accumulation was expressed as a fold increase in luciferase
activity over the DMSO control.
Cell viability assay
Calu6,HT29,MDA-MB-231cells(eachat2000cells/well),H460
cells (1000 cells/well) and HCT116 cells (1500 cells/well) were
plated in black clear-bottomed BioCoat
TM PDL-coated 384-well
plates(BDBiosciences).Cellswereincubatedwithcompoundfor
72 h,afterwhichthemediumwasremovedtoleave25 μlperwell.
An equal volume of ATPlite
TM reagent (PerkinElmer) was then
added and luminescence was measured using a LEADseeker
TM
instrument.
siRNA (small interfering RNA) transfection and assay
MDA-MB-231 4xUb-Luc cells were transfected in a 384-
well format with 10 nM siRNAs (siGENOME SMARTpool,
Dharmacon) using DharmaFECT 1 (DH1) reagent (Dharmacon)
as follows. For the preparation of the RNAi (RNA interference)
transfection mixture for each time point, 40 μl of OptiMEM I
(Invitrogen) was dispensed into duplicate wells of a 384-well
plate each containing 9 μl/well of 0.5 μM siRNA in siRNA
buffer (Dharmacon). OptiMEM (50 μl) containing 0.53 μlo f
DH2 transfection reagent (Dharmacon) was then added to each
wellandtheplateswereincubatedatroomtemperature(22◦C)for
20 min.Thetransfectionmixture(14 μl)fromduplicatewellswas
thentransferredintosixreplicatewellsoftwoseparateBioCoat
TM
PDL-coated384-wellcellplates(BDBiosciences),onefor4xUb-
Luc assay and one for ATPlite assay (white and black clear-
bottomed respectively). Reverse transfection was performed by
the addition of 50 μl of MDA-MB-231 4xUb-Luc cells to each
well to give 1200 cells/well. At 48, 72 or 96 h after transfection,
one set of duplicate plates was assayed for 4xUb-Luc reporter
activity and cell viability. For each time point, six replicate wells
of cells transfected with buffer only and the non-targeting GL2
luciferase control duplex were each treated with either DMSO
or 1 μM bortezomib for 8 h prior to performing the 4xUb-Luc
assay.
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Cell-based Proteasome-GloTM β5 assays
Calu6 cells were plated as for the reporter assays and incubated
with compound for 1 h at 37◦C. B-cell lymphoma subtypes
Karpas-1106P,WSU-DLCL2andOCI-Ly10wereplatedat20000
cells per well in 384-well plates and treated with compounds
identically. The activity of the 26S proteasome was measured
in situ after compound removal by monitoring hydrolysis of
the β5 (chymotrypsin-like) substrate Suc-LLVY-aminoluciferin
(where Suc is succinyl) in the presence of luciferase using the
Proteasome-Glo
TM assayreagentsaccordingtothemanufacturer’s
instructions (Promega). Luminescence was measured using a
LEADseeker
TM instrument.
In vitro assays of puriﬁed 20S
The peptidase activities of puriﬁed human erythrocyte and
peripheralbloodmonocyte20Sproteasomes(BostonBiochem
TM)
were assayed using ﬂuorogenic tri-and tetra-peptide substrates
coupled to AMC (7-amino-4-methylcoumarin) [40] (AnaSpec)
in the presence of recombinant PA28α (proteasomal activator
28α; Boston Biochem
TM). The following selective substrates
were obtained from AnaSpec, with the exception of Z-LLE-
AMC (where Z is benzyloxycarbonyl), which was from Boston
Biochem
TM, and were each used at a ﬁnal concentration of 15 μM
to assay the constitutive (c) and immunoproteasome (i) sub-sites:
β1c, Z-LLE-AMC; β2c, Ac-KQL-AMC (where Ac is acetyl);
β5c, Ac-WLA-AMC; β1i, Ac-PAL-AMC; β2i, Ac-KQL-AMC;
and β5i, Ac-ANW-AMC. Reactions were performed at 37◦Ci n
384-well black microtitre plates (Corning) using 0.25 nM 20S
and 12 nM PA28α in a ﬁnal volume of 50 μl of buffer containing
20 mMHepes,pH 7.4,0.5 mMEDTAand0.01%BSA.Peptidase
activity was measured by monitoring the AMC liberation over
time with a Polarstar Galaxy ﬂuorimeter (BMG Labtechnologies)
usingexcitationandemissionwavelengthsof340 nmand460 nm
respectively. Percentage inhibition of 20S activity was calculated
relative to the controls with DMSO and 10 μM ML599698, an
analogue of bortezomib that contains a phenyl group in place of
the N-terminal pyrazine cap.
In vitro assays of 20S proteasomes in cell extracts
B-cell lymphoma extracts were prepared by hypotonic lysis and
assayedforproteasomeactivityasdescribedpreviously[15]using
10 μg of protein extract per reaction in the presence of 12 nM
PA28α and the following substrates, each at 100 μM, to monitor
the catalytic activity of the c or i 20S sub-sites, as indicated: β1i,
Ac-PAL-AMC; β5i, Ac-ANW-AMC; β5c, Ac-WLA-AMC; and
β5 Suc-LLVY-AMC.
Kinetic analysis of puriﬁed 20S inhibition
Inactivation of puriﬁed human erythrocyte 20S was determined
by monitoring the hydrolysis of the β5-speciﬁc ﬂuorigenic
peptide substrate Suc-LLVY-AMC in the presence of different
concentrations of inhibitor. Substrate cleavage was continuously
monitored as a change in the ﬂuorescence emission at 460 nm
(excitationwavelength,360 nm)andplottedasafunctionoftime.
Assays were performed at 37◦C in cuvettes in a ﬁnal volume
of 2 ml in a reaction buffer containing 20 mM Hepes, pH 7.5,
0.5 mM EDTA, 0.01% SDS, 0.25 nM 20S and 10 μMS u c -
LLVY-AMC, with continuous stirring. The apparent dissociation
constant, Ki
app, was determined by non-linear least-ﬁt of the
fractionalvelocity,vs/v0,asafunctionof[I],wherevs isthesteady-
state residual activity of the enzyme in the presence of inhibitor
(I) and v0 is the initial velocity in the absence of inhibitor:
νs
ν0
=
1
1 +
[I]
K
app
i
The dissociation constant, Ki, was calculated from the apparent
dissociationconstant,Ki
app,usingthefollowingexpression,where
[S] is the substrate concentration and Km is the substrate binding
constant (for 20 μM Suc-LLVY-AMC):
Ki =
K
app
i
1 +
[S]
Km
Protein turnover assay
Bulk protein turnover was measured in HCT116 cells
according to previously published procedures [41], as described
in the Supplementary material at http://www.BiochemJ.org/
bj/430/bj4300461add.htm.
Synthesis of compound 1, the capped tri-peptide
5-methyl-N-((S)-1-((S)-1-((S)-1-(4-methylbenzylamino)-1-oxo-4-
phenylbutan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)-1-oxo-4-
phenylbutan-2-yl)pyrazine-2-carboxamide
The trimeric compound 1 was identiﬁed by LC-MS as
an impurity in an active well identiﬁed during the high-
throughput screen [42] and its structure was conﬁrmed by full
characterization of material prepared according to Scheme 1,
as detailed in the Supplementary Experimental section at
http://www.BiochemJ.org/bj/430/bj4300461add.htm.
Synthesis of capped di-peptide proteasome inhibitors
The synthesis of di-peptide analogues was carried out using
standard peptide-coupling conditions, typically using HBTU
(O-benzotriazole-N,N,N
 ,N
 -tetramethyluroniumhexaﬂuorophos-
phate) to activate the carboxylic acids according to Scheme 2.
The P1 and P2 residues (R1 and R2 respectively) were installed as
described above for the preparation of compound 1 by coupling
the appropriate amine to a Boc (t-butoxycarbonyl)-protected
α-amino acid, followed by de-protection to give intermediates
II as hydrochloride salts. The three-step elaboration of II to
the di-peptide analogues of compound 1 (IV) was carried out
using automated solution-phase parallel synthesis techniques in
deep-well plates without puriﬁcation of intermediates, but with
rigorous puriﬁcation and full characterization of ﬁnal products. A
representative procedure for the parallel synthesis of compound
arrays of IV can be found in the Supplementary Experimental
section.
Puriﬁcation of yeast 20S
Yeast 20S wild-type and open-gate (an N-terminal tail deletion
from the α3a n dα7 subunits, designated α3/7 N) mutant
containing a TEV (tobacco etch virus)-protease-cleavable Protein
A-derived tag in the core particle subunit Pre1 (β4) were afﬁnity-
puriﬁed from the SDL135 and yMS159 strains respectively (gifts
fromDrM.SchmidtandDrD.Finley,HarvardUniversityMedical
School, Boston, MA, U.S.A.) [43,44] on IgG–Sepharose 6 Fast
Flow (GE Healthcare), according to the procedure of Leggett
et al. [45], except that ATP was omitted from the buffers and
the enzyme was eluted from the IgG resin by incubation with the
His6–TEV protease (Invitrogen) overnight at 4◦C. The resultant
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Scheme 1 Synthesis of compound 1
(i) ArCH2-NH2, HBTU, NMM (N-methylmorpholine), DMF (N,N-dimethylformamide), 25◦C, 24h; (ii) 4M HCl, dioxane; (iii) N-Boc-homo-phenylalanine, TBTU [O-(benzotriazol-
1-yl)-N,N,N ,N -tetramethyluronium-tetraﬂuoroborate], collidine, DMF, 25◦C, 3h; (iv) 4-methylpyrazinecarboxylic acid, TBTU, collidine, DMF, 25◦C, 3h.
Scheme 2 Synthesis of compound IV
(i) R1-NH2, HBTU, NMM (N-methylmorpholine), DMF (N,N-dimethylformamide), 25◦C, 24h; (ii) 4 M HCl, dioxane; (iii) P3 Boc-amino acid, HBTU, NMM, DMF, 25◦C, 24h; (iv) R4COOH, HBTU,
NMM, DMF, 25◦C, 24h.
yeast20Swaspuriﬁedfurtherbygelﬁltrationona24 mlSuperose
6 10/30 column (GE Healthcare) in 10 mM Tris/HCl, pH 7.5,
containing 1 mM EDTA, concentrated to 30 mg/ml using an
Amicon Centriplus YM-100 centrifugal ﬁlter device (Millipore)
a n ds t o r e da t−80◦C.
X-ray crystallography
Crystals of puriﬁed wild-type and the open-gate mutant yeast 20S
proteasome were grown in hanging drops at room temperature,
as described previously [46], using a drop volume of 1.5 μl
of 20S (20 mg/ml in 10 mM Tris/HCl, pH 7.5, and 1 mM
EDTA) and 0.5 μl of reservoir solution containing 100 mM
Mes, pH 7.0, 40 mM Mg(CH3COO)2,1 5% MPD (2-methyl-2,4-
pentanediol)and10 mMEDTA.Proteasome–inhibitorcomplexes
were generated by soaking crystals overnight in reservoir
buffer containing 1 mM compound, 10% DMSO and 20%
M P Df o l l o w e db ya na d d i t i o n a l5 hi nr e s e r v o i rb u f f e r
containing 1 mM compound, 10% DMSO and 25% MPD
before being ﬂash-cooled in liquid nitrogen. Crystal data and
reﬁnement statistics are given in Supplementary Table S1 at
http://www.BiochemJ.org/bj/430/bj4300461add.htm. Data were
collected using the Structural GenomiX (SGX)-CAT beamline at
the Advanced Photon Source (APS) synchrotron of the Argonne
National Laboratory (U.S. Department of Energy Chicago, IL,
U.S.A.) and processed using the programs iMOSFLM [47] and
SCALA [48]. Starting co-ordinates for each of the proteasome–
inhibitor structures were taken from PDB entry 1G0U [43].
SigmaA-weighted Fo −Fc difference electron density for the β5
active site was used to model inhibitor co-ordinates, starting
withaconformationgeneratedusingthesmall-moleculetopology
generator PRODRG [49]. Model building was performed using
the program Coot [50] and reﬁnement was carried out using the
CCP4i graphical user interface [51] to the REFMAC program
[52].
RESULTS
Cell-based screen for inhibitors of the UPS
Toidentifynovelcell-activesmall-moleculeinhibitorsoftheUPS,
a high-throughput screen of the Millennium Pharmaceuticals,
Inc., library was performed for compounds that stabilized 4xUb-
Figure 2 Effects of bortezomib and depletion of 26S subunits by RNAi on
accumulation of 4xUb-Luc in cells
MDA-MB-231cellsstablyexpressinga4xUb-Lucreporterwerereverse-transfectedwith10nM
siRNA SMARTPools to deplete components of the 19S regulatory cap or 20S catalytic core
particleofthe26Sproteasome,asindicated.At48,72or96haftertransfection,theaccumulation
ofthe4xUb-Lucwasmeasuredasluminescenceusingﬁreﬂyluciferasereagents,asdescribedin
theExperimentalsection.MocktransfectionswithbufferorwiththeGL2luciferasecontrolduplex
were also performed to monitor basal expression of the 4xUb-Luc reporter and its stabilization
by 1μM bortezomib for the ﬁnal 8h of transfection. Results are the means+ −S.E.M. for six
assaypointsandarerepresentativeoffourindependentexperiments.PSMA,proteasomesubunit
α-type; PSMB, proteasome subunit β-type; PSMD, proteasome 26S subunit non-ATPase; rpn,
regulatory particle non-ATPase.
Luc in MDA-MB-231 cells. In this system, bortezomib and
other catalytic 20S inhibitors cause a concentration-dependent
accumulation of the constitutively expressed reporter by blocking
its intracellular degradation, as reported previously [15]. To
further validate the dependence of this reporter on the 26S
proteasome,siRNAswereusedtodepleteselectedcomponentsof
the 20S core particle and 19S regulatory complex in MDA-MB-
231-4xUb-Luc cells. As shown in Figure 2, depletion of subunits
of either the 20S (α1a n dβ6) or 19S (rpn8 and rpn11) complex
resulted in a time-dependent increase in the 4xUb-Luc signal
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Figure 3 Structure of the capped tri-peptide screening hit, 5-methyl-
N-[(S)-1-{(S)-1-[(S)-1-(4-methylbenzylamino)-1-oxo-4-phenylbutan-
2-ylamino]-1-oxo-4-phenylbutan-2-ylamino}-1-oxo-4-phenylbutan-2-
yl]pyrazine-2-carboxamide, compound 1
comparable with that observed by an 8 h treatment of the cells
with a near-saturating concentration of bortezomib of 1 μM.
High-throughput screening of approx. 352500 compounds at
50 μM gave 3015 hits that stabilized 4xUb-Luc by 2-fold or
greater, representing a primary hit rate of 0.86%, and 611 of
these positives were conﬁrmed when re-tested in triplicate at
the same concentration and cut-off, representing a re-test rate
of 20.3%. The majority of these compounds were either peptide
boronic acid inhibitors of the proteasome or ubiquitin-activating
enzyme (E1) inhibitors that were part of the library generated
by proprietary medicinal chemistry and served as screening
controls. There were 191 compounds which were previously
uncharacterized as inhibitors of the UPS, for which cell-based
potencydeterminationswereperformed.Ofthese,52gavemodest
2–3-fold stabilization, whereas 102 compounds gave a 3–10-fold
stabilization and 37 compounds gave >10-fold stabilization of
the reporter at concentrations up to 50 μM.
Identiﬁcation of compound 1 as a potent selective 20S β5 inhibitor
Thecell-activecompoundswereassessedforinhibitionofpuriﬁed
rat brain 20S in vitro by measuring hydrolysis of the β5
(chymotrypsin-like) substrate Ac-WLA-AMC in the presence
of PA28α. Only a small minority of compounds inhibited 20S,
showing low and sub-micromolar potencies (results not shown).
Among the most potent of these were four closely related
peptidic benzyl amides synthesized by combinatorial chemistry,
of which one was subsequently identiﬁed by MS and re-synthesis
as a C- and N-terminally capped tri-peptide derived from the
unnatural amino acid S-homo-phenylalanine, and designated as
compound 1 (Figure 3) In vitro, this compound inhibited the
β5 activity of the human constitutive and immunoproteasome
with low nanomolar potencies, comparable with those of
bortezomib, but was essentially inactive against the β1 (caspase-
like) and β2 (trypsin-like) sites of either proteasome isoform
(Table 1). β5 selectivity is in contrast with that of bortezomib,
which also inhibits the β1 and, to a lesser extent, the β2
sites of the constitutive and immunoproteasome (Table 1).
Assays against a diverse panel of ten proteases indicated that
compound 1 was highly selective for the proteasome, showing
only partial (<50%) inhibitory activity against cathepsin L,
coagulation Factor β-XIIa, thrombin, tissue plaminogen activator
and trypsin at concentrations approx. 10000-fold higher than
its IC50 value for the 20S β5 site (Supplementary Table S2
at http://www.BiochemJ.org/bj/430/bj4300461add.htm). Kinetic
analysis of human 20S β5 inhibition by compound 1 showed
that it behaved as a rapid-equilibrium inhibitor with a Ki
Figure 4 Kinetics of proteasome inhibition by compound 1 and bortezomib
(A and B) The peptidase activity of human erythrocyte 20S (0.25nM) was monitored over
time using the ﬂuorigenic substrate Suc-LLVY-AMC (10μM) in the presence of 0.01% SDS
and following the addition of various concentrations of either compound 1 or bortezomib, as
indicated.(C)Anon-linearleast-ﬁtofthefractionalvelocityofthereactions,vs/v0,asafunction
of inhibitor concentration, [I], was used to determine a Ki of 0.50+ −0.12nM for compound 1
and 0.56+ −0.072nM for bortezomib (means+ −S.E.M., n=3).
value of 0.50+ −0.12 nM (mean+ −S.E.M., n=3), consistent with
reversible non-covalent binding to the active site of the enzyme
(Figure 4). This behaviour is again in contrast with that of
bortezomib, which acts as a time-dependent slow–tight binding
inhibitorthatinteractscovalentlywiththeactivesiteThr
1 residue,
but which displays an equivalent Ki value for the β5 site of
0.56+ −0.072 nM (mean+ −S.E.M., n=3) (Figure 4 and [25]).
Cellular inhibition of proliferation, 4xUb-Luc degradation,
NFκB-Luc activation by compound 1
On the basis of the high afﬁnity and selectivity of compound 1 for
the 20S β5 site in vitro, its activity was characterized further in
cells as compared with that of bortezomib. Compound 1 inhibited
the proliferation of MDA-MB-231 cells in a concentration-
dependent manner with an LC50 (half-maximal lethal
concentration) value of 150+ −23 nM (mean+ −S.E.M., n=3),
as determined by an ATPlite assay at 72 h (see Supplementary
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Table 1 Active-site-selectivity of the peptide boronic acid, bortezomib, the capped tri-peptide screening hit, compound 1, and a series of ﬁfteen capped
di-peptides in vitro
Puriﬁed human erythrocyte 20S and peripheral blood monocyte 20S (0.25nM each) were used as a source of constitutive (c) and immunoproteasome (i) respectively to measure the peptidase
activity of the β1 (caspase-like), β2 (trypsin-like) and β5 (chymotrypsin-like) sub-sites of each proteasome isoform. Assays were performed in the presence of 15μM of the indicated ﬂuorigenic
peptide-AMC substrate, 12 nM PA28α and a titration of each inhibitor. As shown, and unlike bortezomib, compounds 1–16 were essentially inactive against the β1a n dβ2 sites of the constitutive
proteasome and immunoproteasome. The IC50 values of the compounds against the β5c and β5i sites are mean values for at least three independent determinations.
Human 20S–PA28 IC50 (nM)
Compound β1c Z-LLE-AMC β1i Ac-PAL-AMC β2c Ac-KQL-AMC β2i Ac-KQL-AMC β5c Ac-WLA-AMC β5i Ac-ANW-AMC
Bortezomib 140 5.5 1500 940 8.2 3.3
1 28000 >100000 57000 >100000 16 8.9
2 83000 >100000 >100000 >100000 1100 230
3 43000 65000 54000 47000 130 37
4 48000 >100000 >100000 >100000 470 41
5 39000 >100000 >100000 70000 340 27
6 >100000 >100000 >100000 44000 25 10
7 70000 >100000 >100000 91000 9100 1300
8 31000 83000 63000 47000 13 4.1
9 68000 >100000 >100000 >100000 6.8 6.7
10 90000 >100000 >100000 >100000 4.6 3.2
11 >100000 >100000 >100000 >100000 2.4 1.1
12 89000 >100000 95000 >100000 4.4 3.5
13 84000 >100000 99000 >100000 3.9 3.4
14 66000 >100000 >100000 >100000 11 200
15 64000 >100000 >100000 >100000 12 44
16 >100000 >100000 >100000 >100000 1.2 1.1
Figure S1A at http://www.BiochemJ.org/bj/430/bj4300461add.
htm). Indeed, viability assays performed across a panel
of ﬁve cancer cell lines, comprising MDA-MB-231, Calu6,
H460, HCT116 and HT29 cells, indicated that compound
1 has broad cytotoxic activity, with LC50 values ranging
from 50 nM to 380 nM and being approx. 10–20-fold less
potent than bortezomib (Table 2 and Supplementary Table S3
at http://www.BiochemJ.org/bj/430/bj4300461add.htm). In the
screening assay, compound 1 caused up to an approx. 100-
fold accumulation of the 4xUb-Luc reporter at 8 h [maximal
effect of 52+ −16-fold, with an EC50 (half-maximally effective
concentration)of690+ −22 nM(mean+ −S.E.M.,n=6)],showing
an approx. 3-fold higher EC50 and one-seventh of the efﬁcacy of
bortezomib [maximal effect, 340+ −12-fold; EC50 =240+ −21 nM
(mean+ −S.E.M., n=102)] (Supplementary Figure S1B and
Table 2). The activity of compound 1 was also assessed
in the Proteasome-Glo
TM assay that measures directly the
peptidase activity of the β5 site of the 26S proteasome in
cells using the luminogenic substrate Suc-LLVY-aminoluciferin.
Treatment of Calu6 cells for 1 h with compound 1 caused a
concentration-dependent inhibition of β5 activity in this assay
with an IC50 (half-maximal inhibitory concentration) value of
53+ −16 nM (mean+ −S.E.M., n=3). Bortezomib was approx.
10-fold more potent, inhibiting hydrolysis of the chymotrypsin-
like substrate with an IC50 of 3.9+ −0.49 nM (mean+ −S.E.M.,
n=8) (Supplementary Figure S1C and Table 2). Finally,
we assessed the effect of compound 1 on activation of the
transcription factor NFκBb yT N F - α, which is dependent on
proteasomal degradation of IκBα (inhibitory protein of NFκB
α) following its rapid phosphorylation by the IκBk i n a s e
complex and ubiquitination by the SCF
βTrCP (E3 ubiquitin-
protein ligase complex Skp1–Cullin–F-box) [53]. Compound
1 inhibited TNFα-induced activation of NFκB-Luc in HEK-
293 cells with an IC50 of 47+ −7.7 nM (mean+ −S.E.M., n=7),
consistent with potent proteasome inhibition in these cells.
Interestingly, it did not fully inhibit NFκB-Luc, even at saturating
concentrations[maximalinhibition,79+ −3.2%(mean + −S.E.M.,
n=7)], whereas bortezomib inhibited NFκB-Luc activity by
100% with an IC50 of 9.7+ −0.73 nM (mean+ −S.E.M., n=14)
(Supplementary Figure S1D and Table 2). Collectively, these data
indicate that selective inhibition of the β5 site of the proteasome
by compound 1 in cells is sufﬁcient to inhibit the degradation of
the 4xUb-Luc reporter, TNF-α-dependent NFκB activity and the
proliferationofcancercellswithpotenciesthatareapproximately
one order of magnitude lower than those of bortezomib.
X-ray crystallography of compound 1 in complex with the yeast 20S
proteasome
To determine its binding mode, compound 1 was soaked into
crystals of the yeast 20S core particle. X-ray diffraction data
obtained at 3.1 Å resolution indicated that it only occupied
the β5 sites of the proteasome (Figure 5A), consistent with
selective inhibition of this active site in vitro. The C-terminal
4-methylbenzyl group (P1) was seen to occupy a well-deﬁned S1
pocket, with the ﬁrst homo-phenylalanine residue (P2) pointing
toward solvent, the second (P3) occupying a well-deﬁned S3
pocket and the third (P4) projecting into a much larger and ill-
deﬁned S4 pocket (Figure 5B). No electron density was observed
corresponding to the N-terminal cap, presumably because this
region of the molecule is disordered. The structure of compound
1overlaidwiththatofbortezomib,asdeterminedpreviously[26],
suggests that, although the side chains of the two compounds
differ in their orientations, most of the backbone hydrogen-bond
interactionswithintheβ5sitearethesame(Figure5C).Ofnote,in
this structure as in others, residual electron density corresponding
to Mes, the buffer in which the crystals were prepared, was
observed near Thr
1 in the β5 active site (Figure 5A). The main
interaction between Mes and compound 1 involves hydrophobic
contacts between the morpholino group of Mes and the homo-
phenylalanine residue in the P2 position. For structures without
ligand in the active site, no density for the morpholino group
was observed (M.D. Sintchak, unpublished work), rather electron
densityatthepositionofthesulfuratomofMeswasseen.Thissits
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Table 2 Cell-based activity of bortezomib, compound 1 and ﬁfteen capped di-peptide proteasome inhibitors
Thecell-basedpotenciesofbortezomibandcompounds1–16wereassessedinadiversepanelofassaysthatmonitortheshort-andlonger-termeffectsofproteasomeinhibitionincells,asindicated.
In particular, inhibition of the β5 activity of the proteasome was measured directly with the Proteasome-GloTM assay using Suc-LLVY-aminoluciferin as substrate following incubation of Calu6 cells
(10000 per well) with compound for 1h. Inhibition of NFκB-luciferase activity in HEK-293 cells was determined by pre-incubation of the cells (10000 per well) with compound for 1h followed
by stimulation with 10ng/ml TNF-α in the continued presence of compound for 3 h. The IC50 and percentage inhibition of NFκB-Luc activity are given. Accumulation of the 4xUb-Luc reporter in
MDA-MB-231 cells was determined by incubation of the cells (10000 per well) with compound for 8 h and expressed as the fold accumulation of luciferase activity together with an EC50 value
for this effect. The effects of the compounds on the viability of Calu6 cells (2000 per well) and H460 cells (1000 per well) were assessed by the ATPlite assay following incubation of the cell with
compound for 72h. The results are mean values for at least three independent experiments.
Calu6 Proteasome-GloTM β5 HEK-293 NFκB-Luc MDA231 4xUb-Luc Cell viability
Compound IC50 (nM) IC50 (nM) Maximal inhibition (%) EC50 (nM) Maximal induction (fold) Calu6 LC50 (nM) H460 LC50 (nM)
Bortezomib 3.9 9.7 100 240 340 5.2 13
1 53 47 79 690 52 130 380
2 48000 >50000 28 1800 3 >25000 >25000
3 610 3100 84 2100 39 1700 3100
4 13000 24000 30 6900 12 13000 18000
5 12000 >50000 16 4700 28 2000 2600
6 310 320 89 2100 76 1200 4300
7 5400 4400 86 10000 65 6600 17000
8 43 29 87 930 86 240 470
9 10 22 78 130 77 10 34
10 16 6.6 72 47 64 55 82
11 5.7 9.8 93 112 65 21 110
12 36 10 74 71 64 36 110
13 24 9.2 77 64 76 61 240
14 520 64 77 650 64 210 650
15 230 39 80 450 82 355 1000
16 9.5 12 92 31 75 9.6 44
at the same position as the nucleophilic water molecule referred
to as NUK in a previous publication [54]. Importantly, although
Mes was observed in the active site following crystallization, this
buffer molecule neither affects the speciﬁc activity of 20S nor the
afﬁnity of compound 1 for the active site on the basis of Ki value
determination (F.J. Bruzzese, unpublished work).
Optimization of capped di-peptide 20S inhibitors
The partial crystal structure of compound 1 (Figure 5) together
with the report of a potent related tri-methoxy-phenylalanine-
containing tri-peptide 20S inhibitor (Figure 1 and [38]) suggested
that one homo-phenylalanine residue could be deleted, provided
thatacompensatinghydrophobicN-terminalcappinggroupcould
be incorporated in place of the pyrazine. A series of di-peptide-
like libraries was therefore prepared by solution-phase parallel
synthesis as outlined in the Experimental section (Scheme 2),
denoting residues P1–P4 (Figure 6) according to the binding
mode indicated by the structure of compound 1 (Figure 5). Given
the close correlation in IC50 values of proteasome inhibitors
from various chemical classes for human and yeast 20S (C.
Tsu, unpublished work), compounds were optimized for in vitro
β5 potency against human 20S, whereas crystal structures of
representativeexamplesweredeterminedwiththeyeast20Sopen-
gate mutant in order to guide further library design.
The ﬁrst library synthesized retained 4-methylbenzylamine as
the C-terminal capping group at P1, contained varied amino acid
residues at P2 and P3 and probed two alternative hydrophobic
N-terminal caps at P4 with 348 compounds in total. All of these
di-peptide analogues were less potent than the trimer compound
1, although several inhibited β5 activity with low and sub-
micromolar potencies. For example, the truncated analogue of
compound 1 with an N-terminal cap substitution, compound 2
(Figure 7), had a β5I C 50 value of 1.1 μM in vitro (Table 1).
Substitution of the homo-phenylalanine residues of compound
2 by a tryptophan at P1 and by the di-methoxy-phenylalanine
residue [38] at P2 gave compound 3 (Figure 7) with a β5
IC50 value of 130 nM (Table 1). In the next library, smaller
replacements for the P3 homo-phenylalanine residue were sought
incombinationwithalternativeN-terminalP4cappinggroupsthat
provided compensating hydrophobic interactions within the large
S4 binding pocket. Numerous compounds, such as compound 4
and the 4-benzyloxybenzoyl derivative compound 5, with small
polar P3 residues, in this case a threonine residue (Figure 7),
retained reasonable potency in vitro (β5I C 50 values of approx.
500 nM). Signiﬁcant further improvements were effected by
varying the capping group, with the indanone in compound 6
being among the optimal residues at P4 with this compound
showing a β5I C 50 of 25 nM (Figure 7 and Table 1) and a Ki
value of 13+ −1.4 nM (mean+ −S.E.M., n=3).
The crystal structure of compound 6 bound to the β5 site
of yeast 20S was determined at 2.6 Å resolution (Figure 8)
and compared with that of bortezomib determined at 2.7 Å, a
resolutioncomparablewiththatdeterminedpreviously[26].Inthe
structure ofbortezomib, in addition to the covalent andhydrogen-
bonding interactions involving the boronate, backbone hydrogen-
bonding interactions with the β5 site can be seen (Figure 8A).
Interestingly, the same hydrogen-bonding interactions between
the backbone of compound 6 and the β5 site are observed,
including the presence of the bridging water molecule between
the P3 carbonyl group and Ala
49 and Ala
50 (Figure 8A).
Figures 8(B) and 8(C) show the occupancy of the binding
pockets by compound 6, whereas Supplementary Figure S2
(at http://www.BiochemJ.org/bj/430/bj4300461add.htm) shows
an alternative view to include the electron density of the water
molecule. The 4
 -methylbenzyl P1 residue occupies S1, with
the methyl group occupying a small sub-pocket at the bottom
of the cavity. The P2 homo-phenylalanine residue occupies
S2 and the P3 threonine residue projects, to a small degree,
towards the deep S3 binding pocket. The P2 homo-phenylalanine
residue does not ﬁll the S2 binding pocket, which is quite
shallow, but likely confers potency by contributing a hydrophobic
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Figure 5 Electron-density map of compound 1 and occupancy of the speciﬁcity pockets of the 20S β5 subunit
(A)A3 . 1A ˚ sigmaA-weighted 2Fo-Fc electron-density map contoured at 1.0σ covering compound 1 (PDB entry 3MG4) and Mes in the β5/β6 active site of wild-type 20S is shown in stereo view,
with residue positions P1–P4 indicated. Atoms are in ball-and-stick representation with carbon in yellow (compound 1) or salmon (Mes), nitrogen in blue and oxygen in red. The side chain atoms
for Thr1 (β5) and Asp114 (β6) are shown in ball-and-stick representation, coloured as above, except for carbon in green. Protein atoms from 20S are shown in cartoon representation coloured
by secondary structure with helices in cyan, β-strands in magenta and loops in salmon. The Figure was made using the PyMOL Molecular Graphics System (DeLano Scientiﬁc, Palo Alto, CA,
U.S.A.). (B) The β5/β6 active site with compound 1 bound (coloured as in A), showing the molecular surface of 20S. Speciﬁcity pockets S1–S4 are indicated. (C) Superposition of compound 1
and bortezomib bound to the β5/β6 active site of 20S is shown, with positions P1–P4 indicated. Colour scheme is as described above, except bortezomib carbon atoms are coloured grey.
interaction at a ‘ledge’ formed from Gly
47-Gly
48 (Figure 8C).
Of note, the P4 indanone in compound 6 is closely related to
inhibitors reported previously [35,36], for example, CVT-659
(Figure 1B). Whereas the indanone carbonyl in these molecules
was originally designed as a ‘putative electrophilic head group’
[35,36], the crystal structure of compound 6 places this moiety
in the S4 binding pocket remote from the β5 catalytic Thr
1
residue, thereby precluding such an interaction. In addition, the
water molecule appears to be present in all higher-resolution
structures (<2.6 Å), including those without ligand bound,
such as that reported originally [54]. This water molecule was
also observed in structures with inhibitors having IC50 values
greater than 1 μM (M.D. Sintchak, unpublished work). Therefore
it is unlikely that this single water-mediated hydrogen bond
contributes signiﬁcantly to potency.
In the third library, optimization of the C-terminal P1
residue was explored. The requirement of the hydrogen-bonding
interaction with Gly
47 can be seen from N-methylation of P1 to
give compound 7 (Figure 7), which diminished activity greatly
(β5I C 50 =9.1 μM; Table 1). However, comparable potency
with compound 6 was observed for the 2
 -chlorobenzyl derivative
compound 8 (β5I C 50 =13 nM; Table 1 and Figure 7). A crystal
of compound 8 bound to 20S indicated an additional hydrophobic
interaction between the ortho-halogen and a second ‘sub-pocket’
within the S1 site that cannot be accessed by the less active meta-
substituted analogue ([42] and see Supplementary Figure S3 at
http://www.BiochemJ.org/bj/430/bj4300461add.htm).
In the ﬁnal library, the inﬂuence of a hydrophobic P3 residue
was assessed, with emphasis on asparagine derivatives. As with
the potency-enhancing N-terminal P4 capping groups described
above, several low nanomolar inhibitors were identiﬁed, such
as compounds 9 (β5I C 50 =6.8 nM, Table 2) and 10 (β5
IC50 =4.6 nM, Table 2) (Figure 7). Potent compounds such
as 11 (β5I C 50 =2.4 nM, Table 1) and 12 (β5I C 50 =4.4 nM,
Table 1) in which the homo-phenylalanine residue was replaced
by an alanine residue and compound 13 (β5I C 50 =3.9 nM,
Table1),inwhich3-pyridylwasincorporated,werealsoidentiﬁed
(Figure7).Similarly,theneopentyl-asparagineresiduewasableto
compensate for sub-optimal interactions in S1, with compounds
14 and 15 showing good inhibitory activity (β5I C 50 =11 and
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Figure 6 Residue assignments of di-peptide inhibitors
Optimization of compound 1 involved contracting the chain to a di-peptide of the general
structure shown and systematically modifying the central amino acids and capping groups,
as denoted by residues P1–P4 in a series of compound libraries prepared by solution-phase
parallel synthesis (see the Experimental section).
12 nMrespectively;Table1andFigure7).Likecompound1,these
di-peptides at 100 μM had negligible to modest activity against
ten unrelated proteases (Supplementary Table S2), indicating that
the most potent compounds are selective for the chymotrypsin-
like site of the proteasome by 4 or 5 orders of magnitude.
Themostpotentproteasomeinhibitoridentiﬁedwascompound
16 (Figure 7) with a β5I C 50 =1.2+ −0.35 nM for the human
enzyme(Table1)andaKi belowthe20Sconcentrationof250pM
in the assay, indicating that it behaved as a non-covalent active-
site titrant (F.J.Bruzzese,unpublishedwork). TheX-ray structure
of this compound bound to yeast 20S resolved at 2.6 Å is shown
in Figure 9. The potentially electrophilic α-ketoamide N-terminal
cap does not form any covalent interactions; it is positioned in
the S4 binding pocket which is located away from the catalytic
Thr
1 and it also does not appear to interact with any residues
in S4 (Figure 9A). Importantly, the high potency of compound
16 and all compounds with a P3 neopentyl-asparagine group can
be accounted for by the near-optimal ﬁt of this residue in the S3
bindingpocket(Figure9B).Aswithcompound8(Supplementary
Figure S3), the P1 ortho-chlorine of compound 16 is also likely
to contribute to the potency by accessing the S1 sub-pocket
(Figure 9A). Of note, however, the aromatic P2 contains only
one methylene and therefore the ledge interaction cannot take
place with the pyridyl projecting toward solvent (compare with
Figure 8C).
Relationship between 20S β5 potency and cellular activity of
capped di-peptides
The effects of the di-peptides on 26S activity in cells were
measured (Table 2) and compared with their 20S β5I C 50 values
determined in vitro (Table 1 and Supplementary Figure S4 at
http://www.BiochemJ.org/bj/430/bj4300461add.htm). Inhibition
of the β5 site of the 26S proteasome was measured directly in
Figure 7 Chemical structures of capped di-peptide 20S β5 proteasome inhibitors
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Novel non-covalent proteasome inhibitors 471
Figure 8 Hydrogen-bonding interactions and crystal structure of compound 6 bound to the chymotrypsin-like site of the 20S proteasome with reference to
bortezomib
(A) Schematic representation of the β5/β6 active site of 20S with compound 6 (left-hand panel) (PDB entry 3MG6) and bortezomib (right-hand panel) (PDB entry 3MG0) bound. Key hydrogen
bonds between the inhibitors and the protein are shown as dashed lines coloured magenta, with distances indicated in A ˚. Thus in the structure of bortezomib, the NH of the P1 leucine residue forms
a hydrogen bond with the carbonyl of Gly47, whereas the carbonyl and amino groups of the P2 residue form hydrogen-bond interactions with Thr21. The carbonyl of the pyrazinoyl cap is involved in
a network of hydrogen-bond interactions with Ala49,A l a 50 and Asp114 that includes a bridging water molecule. Similar hydrogen-bonding interactions between the backbone of compound 6 and the
β5 site are shown, including the presence of the bridging water molecule between the P3 carbonyl and Ala49 and Ala50; the NH of P3 makes the hydrogen-bond interaction with Asp114 that is formed
by the pyrazine N in bortezomib. (B)2 . 6A ˚ sigmaA-weighted 2Fo-Fc electron-density map contoured at 1.0σ covering compound 6 (PDB entry 3MG6) and MES is shown in the β5/β6 active site of
yeast 20S open-gated mutant in stereo view, with positions P1–P4 indicated. The colour scheme is as described in Figure 5. (C) β5/β6 active site with compound 6 bound (coloured as described
above), showing the molecular surface of 20S. Speciﬁcity pockets S1–S4 are indicated. The P2 binding ‘ledge’ is shown by shading of the molecular surface.
Calu6 cells using the Proteasome-Glo
TM assay and corresponded
well with the inhibitory potencies determined in vitro with
puriﬁed 20S. There was also a striking correlation between
the IC50 values of the compounds for inhibition of NFκB-Luc
activity in cells and 20S β5 activity in vitro,w i t hﬁ v eo f
the analogues, speciﬁcally compounds 10–13 and 16, showing
inhibitory NFκB potencies in the range 6.6–12 nM, equivalent to
orgreaterthanthatofbortezomib[NFκB-LucIC50 =13+ −2.0 nM
(mean+ −S.E.M., n=6)]. Interestingly, the activity of NFκB-
Luc was not fully inhibited even at saturating compound
concentrations(Table2).Thedi-peptidesalsostabilizedthe4xUb-
Luc reporter in MDA-MB-231 cells with EC50 values that tracked
closely with their in vitro 20S β5 potencies (Table 2), although
the maximal stabilization effects of approx. 100-fold were lower
than those observed for bortezomib (Table 2), other boronates
(J.L. Blank, unpublished work) and covalent inhibitors, such as
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Figure 9 Crystal structure of compound 16 bound to the chymotrypsin-like
site of the 20S proteasome
(A) β5/β6 active site with compound 16 (PDB entry 3MG8) bound to yeast open-gated 20S,
showing the molecular surface of 20S (coloured as described in Figure 5). Selectivity pockets
S1–S4 are indicated. (B) Close-up view of the S3 speciﬁcity pocket to illustrate occupancy by
the neopentyl-asparagine residue of compound 16 in the β5/β6 active site of the 20S core
particle (coloured as described above).
salinosporamide A [15]. Finally, the cytotoxic LC50 values of
these compounds also correlated well between cell lines (Table 2)
and with their 20S β5 potencies (Table 1). Interestingly, none
of the compounds were as potent as bortezomib in this assay,
although several gave LC50 values that were approx. 100 nM or
less in at least one cell line, speciﬁcally compounds 9–13 and
16 (Table 2). Signiﬁcantly, each of these contained the neopentyl-
asparaginesubstituentinP3(Figure8),indicatingthatthisresidue
contributes to both in vitro and cell-based potency. Furthermore,
since these compounds were also the most potent inhibitors of
NFκB-Luc activity, these data strongly suggest that their effects
on cell viability and NFκB activity are mediated by proteasome
inhibition.
Effect of 20S β5 inhibition on bulk protein turnover
The majority of intracellular proteins are degraded by the
proteasome, as demonstrated using inhibitors that irreversibly
inactivate each of the 20S active sites [4]. The effect of
selectively inhibiting the β5 site alone on the degradation
of short-lived protein was assessed using compounds 10 and
16, two of the most potent cell-active di-peptides. As shown
previously [41], bortezomib inhibits approx. 50% of bulk protein
turnover in HCT116 cells (see Supplementary Figure S5 at
http://www.BiochemJ.org/bj/430/bj4300461add.htm), an effect
that is comparable with that observed with ML858, a synthetic
version of salinosporamide A that irreversibly inhibits each of
the 20S active sites [15] (T.A. Soucy, unpublished work). Under
identical conditions, the di-peptides reduced protein turnover
by approx. 20% (Supplementary Figure S5), indicating that
inhibitionoftheβ5sitealoneresultsinpartialinhibitionofprotein
degradation.
Constitutive and immunoproteasome selectivity of di-peptide
proteasome inhibitors
In addition to monitoring the β5 inhibitory potency of the capped
di-peptides using puriﬁed human erythrocyte constitutive 20S
proteasomes, IC50 values were also obtained for the β5i site of
the immunoproteasome from human peripheral blood monocytes
using the selective substrates Ac-WLA-AMC and Ac-ANW-
AMC respectively (Table 1). Bortezomib, compound 1 and the
majority of the capped di-peptides were non-selective in these
assays, inhibiting the constitutive and immunoproteasome with
similar IC50 values, although they tended to inhibit β5i with
slightly greater potencies (Table 1). In common with compound
1, the di-peptides were essentially inactive with respect to
inhibition of the β1i or β2i sites of the immunoproteasome.
However, a limited number of compounds showed signiﬁcantly
greater selectivity for the immunoproteasome, with compounds
4 and 5 being the best examples, showing ∼10-fold β5i
selectivity [compound 4, β5i IC50 =41+ −3.3 nM and β5c
IC50 =470+ −96 nM; compound 5, β5i IC50 =27+ −2.7 nM and
β5c IC50 =340+ −31 nM (means+ −S.E.M., n=3)]. Conversely,
compounds 14 and 15 showed the reverse selectivity, the
former of these two compounds being 18-fold more selective
for the constitutive proteasome [β5c IC50 =11+ −2.3 nM; β5i
IC50 =200+ −62 nM (means+ −S.E.M., n=3)] and the latter
3.6-foldmoreselective[β5cIC50 =12+ −2.8 nM(mean+ −S.E.M.,
n=4);β5iIC50 =44+ −9.2 nM(mean+ −S.E.M.,n=3)](Table1).
To determine whether this selectivity was maintained in cells,
three B-cell lymphoma subtypes were used that differ in their
proteasome isoform expression. As shown in Figure 10(A),
OCI-Ly10 cells do not express the immunoproteasome, as
demonstrated by the negligible hydrolysis of the β1i- and
β5i-speciﬁc substrates Ac-PAL-AMC and Ac-ANW-AMC
respectively, whereas Karpas-1106P express substantial β1i
and β5i activities, indicating considerable enrichment of the
immunoproteasome. The hydrolysis of the β5c substrate Ac-
WLA-AMC supported this expression proﬁle, although it is not
entirely selective for β5c over β5i and therefore over-represents
the amount of constitutive proteasome in Karpas-1106P cells.
The chymotrypsin-like substrate Suc-LLVY-AMC is hydrolysed
approximately equally well by the β5i and β5c sites in vitro,
although cells enriched in the immunoproteasome can show
approx. 2–3-fold higher activity with this substrate. On the basis
of these data, Karpas-1106P cells are highly enriched for the
immunoproteasome, whereas OCI-Ly10 cells only express
the constitutive proteasome. WSU-DLCL2 cells are intermediate
in this activity proﬁle, indicating that they express a mixed
population of the proteasome isoforms.
We assessed the potency of the β5i- and β5c-selective
compounds 5 and 14 respectively in the three B-cell
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Figure 10 Proteasome-subtype selectivity of compounds 5 and 14 in B-cell
lymphomas expressing different levels of the immunoproteasome
(A) The activities of the β1a n dβ5 subunits of the constitutive (c) and immunoproteasome (i)
were assessed in diffuse large B-cell lymphoma extracts (10μg of protein per reaction) using
recombinant PA28α (12nM) and subtype-selective ﬂuorigenic peptide substrates (100 μM),
as indicated. As shown, the rank order of immunoproteasome expression in these cell lines
was Karpas-1106>WSU-DLCL2 LY10. (B and C) The B-cell lymphoma lines (20000 cells
per well) were treated with the indicated concentrations of the immunoproteasome-selective
compound5(B)orconstitutive-selectivecompound14(C)for1 hundercellcultureconditions.
Inhibition of the β5 site of the constitutive and immunoproteasome was then assessed
in situ using the Proteasome-GloTM assay with the chymotrypsin-like luminogenic substrate
Suc-LLVY-aminoluciferin, as described in the Experimental section. As shown, the IC50 values
of compound 5 in Karpas-1106, WSU-DLCL2 and LY10 cells were 200, 380 and 620nM
respectively; the IC50 values of compound 14 in Karpas-1106, WSU-DLCL2 and LY10 cells
were870,120and19nMrespectively.Resultsaremeans+ −S.E.M.fortriplicatedeterminations
and are representative of three independent experiments, the results of which are summarized
in Table 3.
lymphomas using the non-subtype-selective β5 substrate Suc-
LLVY-aminoluciferin in the Proteasome-Glo
TM assay. As shown
in Figure 10(B) and Table 3, the IC50 values of the β5i-selective
compound 5 correlated with immunoproteasome expression
(i.e. the rank order of potency being Karpas-1106P>WSU-
DLCL2>OCI-Ly10), although the differences were relatively
modest (i.e. approx. 4-fold). However, the β5c-selective
inhibitor compound 14, which was the most isoform-selective
compound in vitro, displayed substantial selectivity for the
constitutive proteasome in cells (Figure 10C). The rank order
of effect observed (i.e. OCI-Ly10>WSU-DLCL2>Karpas-
1106P)indicatedanapprox.22-foldincreaseininhibitorypotency
Table 3 Proteasome inhibition in B-cell lymphoma subtypes expressing
differinglevelsofimmunoproteasomebyβ5i-andβ5c-selectivecompounds
5 and 14 respectively compared with bortezomib
Inhibitionoftheβ5sitesoftheconstitutiveandimmunoproteasomewasassessedintheindicated
B-cell lymphoma lines (20000 cells per well) in situ using the Proteasome-GloTM assay. Cells
were incubated with compound for 1 h and assays were performed with the chymotrypsin-like
substrateSuc-LLVY-aminoluciferinasdescribedintheExperimentalsection.Theresultsarethe
means+ −S.E.M. for triplicate determinations.
Proteasome-GloTM β5I C 50 (nM)
Compound OCI-Ly10 WSU-DLCL2 Karpas-1106P
5 1300+ −400 320+ −120 310+ −150
14 39+ −7.6 190+ −76 850+ −240
Bortezomib 2.9+ −0.25 2.7+ −0.26 3.3+ −0.40
of compound 14 in cells that exclusively express the constitutive
proteasome as compared with those that predominantly express
the immunoproteasome. Importantly, bortezomib, which does not
discriminate substantially between β5c and β5i sites in vitro
( T a b l e1 ) ,g a v eI C 50 values that were within 2-fold of each other
in the three B-cell lymphomas (Table 3). These data therefore
provide the ﬁrst description of non-covalent inhibitors of the
proteasomethatcandiscriminatebetweentheimmunoproteasome
and constitutive proteasome in vitro and in cells.
DISCUSSION
The present study has identiﬁed a new series of potent
non-covalent proteasome inhibitors on the basis of a capped
trimeric peptide derived from the unnatural amino acid S-homo-
phenylalanine, ﬁrst identiﬁed by a large-scale high-throughput
cell-basedscreenforsmall-molecule inhibitorsoftheUPS.These
capped di-peptides, prepared by high-throughput liquid-phase
peptide synthesis methods, are entirely selective for the β5 site
over the β1a n dβ2 sites of the 20S core particle, and over a panel
of less closely related proteases. The most potent compounds
show IC50 values in the single-digit nanomolar range for the
human 20S β5 site in vitro, with the best example, compound
16, displaying an IC50 of 1.2 nM and a Ki below the enzyme
concentration in the assay (0.25 nM 20S), indicating that it
behaves as an active-site titrant. In this respect, compound 16
is remarkable in having a greater afﬁnity for the β5 site of the
proteasome than that of the covalent inhibitor bortezomib, which
displays a Ki of 0.56 nM for this site.
Compound optimization was guided by X-ray crystallography
of representative examples bound to the yeast 20S core particle,
whichestablishedtheirnon-covalentbindingmodeandprovideda
structural basis for potency-enhancing modiﬁcations. The crystal
structures of compounds 1, 6, 8 and 16 bound to the 20S β5
active site are shown in Figures 5, 8, S2, and 9 respectively,
and are overlaid in Supplementary Figure S6 (at http://
www.BiochemJ.org/bj/430/bj4300461add.htm).Theoverlaycon-
ﬁrms a common binding mode in which the P1 benzyl group
occupies a well-deﬁned S1 binding pocket, whereas the P2
residue points out towards the solvent, unless it is the homo-
phenylalanine residue in which case a hydrophobic ‘ledge’
interaction can be accessed. The S3 binding pocket is also
well-deﬁned, whereas the S4 pocket is very large and can
tolerate a range of capping groups that are likely to contribute
to potency by picking up further hydrophobic interactions.
This binding mode broadly corresponds to that proposed on
the basis of a homology model [38], except that the crystal
structures obtained in the present study place the N-terminal
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cap in a large S4 binding pocket rather than in small ‘accessory
hydrophobic pockets’, designated previously AS1 and AS2 [38].
Importantly,themostpotentcompoundsidentiﬁedeachcontained
a neopentyl-asparagine substituent in P3, which appears to
provide a near-optimal ﬁt for the S3 binding pocket of the β5
site (Figure 9B). This residue can also be found in the tri-peptide
2-keto-1,3,4-oxadiazoles (Figure 1A) that are slowly reversible
and presumably covalent in nature [11].
Characterization of these compounds in cells demonstrated
that they can functionally inhibit the 26S proteasome with
potencies that correlated well with those determined in vitro
using the puriﬁed enzyme (Table 2 and Supplementary Figure
S4). Furthermore, since the analogues are essentially inactive
againsttheβ1(caspase-like)andβ2(trypsin-like)sitesofthepro-
teasome (Table 1), these data indicate that inhibition of the β5
(chymotrypsin-like) site of the proteasome alone is sufﬁcient
to potently inhibit the degradation of the 4xUb-Luc reporter,
activation of NFκB in response to TNF-α and the proliferation of
cancer cells. Interestingly, despite the fact that the cellular IC50
values of these compounds spanned three orders of magnitude,
withthemostpotentbeinginthesingle-ordouble-digitnanomolar
range, neither the stabilization of 4xUb-Luc nor the inhibition of
the NFκB pathway was complete, even at saturating compound
concentrations (Table 2 and Supplementary Figure S1). These
observations suggest that non-covalent inhibition of 20S β5
activity alone is not sufﬁcient to fully inhibit the proteasomal
degradation of either 4xUb-Luc or IκBα, at least over the time-
scale of these cell-based assays. This is in contrast with the
covalent inhibitors bortezomib and salinosporamide A, which
completely block the degradation of these proteins in cells
and can minimally inhibit both the β1a n dβ5 sites of the
proteasome. Furthermore, estimates of bulk protein turnover in
cells suggest that the overall catalytic rate of proteasome is
reduced, but not abolished, by non-covalent inhibition of the β5
site (Supplementary Figure S5), although it remains a possibility
such inhibition completely blocks the degradation of a subset
of proteins that are only substrates of the β5 site and not the
β1 and/or β2 sites of the proteasome. Importantly, however,
prolonged inhibition of the β5 site alone appears to sufﬁcient
to inhibit cancer cell proliferation.
Proteasome inhibitors that are currently in clinical use do
not discriminate between the chymotrypsin-like activities of the
constitutive or immunoproteasome, and the potential therapeutic
beneﬁt of selective inhibition of either of these activities has not
been demonstrated. However, recent evidence from preclinical
studies with PR-957, a β5i-selective peptide epoxyketone
analogue of carﬁlzomib [28], suggests that the anti-inﬂammatory
effects of proteasome inhibitors, such as bortezomib, may be
mediated by their inhibition of the chymotrypsin-like site of the
immunoproteasome [8]. Our studies have identiﬁed compounds
that differentially inhibit the β5 sites of the constitutive and
immunoproteasome in vitro and in B-cell lymphomas. Of note,
compound5thatpreferentiallyinhibitedtheβ5isitecontainedthe
smallthreonineresidueinP3andthelarger4-methylbenzylamine
aromaticcapinP1.Conversely,thetwoβ5c-selectivecompounds
14 and 15 each contained a smaller residue at P1 and the bulkier
potency-enhancing neopentyl-asparagine in P3 (Figure 8). This
structure–activityrelationship,albeitlimited,isentirelyconsistent
with selectivity data obtained from an approx. 6000 tri-peptide
library screen for substrates that are preferentially hydrolysed
by each active site of the constitutive and immunoproteasome
([55] and C. Tsu, unpublished work). For example, the tri-peptide
substrate Ac-ANW-AMC, where P1 is a tryptophan residue
and P3 is an alanine residue, is preferentially cleaved by the
β5i subunit of the immunoproteasome, whereas Ac-WLA-AMC,
where the P1 and P3 residues are reversed, is preferentially
hydrolysed by the constitutive β5c subunit. The crystal structure
of the immunoproteasome has not yet been determined to provide
an explanation for these selectivity differences. However, the
primary sequences of the mature forms of the human β5c and
β5i subunits are 60.7% identical (see Supplementary Figure
S7 at http://www.BiochemJ.org/bj/430/bj4300461add.htm). We
have therefore mapped the sequence differences between the β5c
and β5i subunits on to the bovine 20S crystal structure [56] and
modelledcompound1intotheactivesite(seeSupplementaryFig-
ure S8 at http://www.BiochemJ.org/bj/430/bj4300461add.htm).
The majority of the sequence differences between β5c and
β5i lie outside of the active site, whereas the residues that
make contacts with compound 1 appear to be mainly the same,
with some relatively minor exceptions, such as the replacement
of Ala
46 and Ser
53 with Ser
46 and Gln
53 within the S1 binding
pocket, Gly
48 with Cys
48 in the S2 ‘ledge’, and the reversal
of the Ala
27-Ser
28 sequence with Ser
27-Ala
28 in the S3 pocket.
Since only subtle differences exist between the ligand-interacting
residues that form the β5c and β5i active sites, it is not
possible to rationalize selectivity differences with respect to
substrate preference or inhibitor sensitivity based on such an
analysis. Clearly, crystal structures of the constitutive and
immunoproteasomes in complex with selective inhibitors will
helpidentifythestructuralfeaturesofeachsub-sitethatcontribute
to selectivity. Finally, although a covalent immunoproteasome-
selective inhibitor has been described recently [8], the function
of the immunoproteasome in cancer cells is unknown. The
identiﬁcation of a new class of proteasome inhibitors, such as
compounds 14 and 5, that preferentially inhibit the 20S β5c
and β5i sites respectively and can thus discriminate between the
constitutive and immunoproteasome in cells may help address
their functional roles in various cellular models of disease
including cancer.
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Figure S1 Activities of compound 1 and bortezomib in cells
(A) The concentration-dependent effects of compound 1 and bortezomib on the proliferation of MDA-MB-231-4xUb-Luc reporter cell line were determined by the ATPlite assay at 72h.
(B) Accumulation of the 4xUb-Luc reporter in the stable MDA-MB-231 cell line was determined by incubation with the indicated concentrations of compounds for 8h followed by luciferase assay.
(C) The β5 activity of the 26S proteasome was measured in Calu6 cells by the Proteasome-GloTM assay using Suc-LLVY-aminoluciferin as a substrate following incubation of the cells with the
indicatedconcentrationofcompoundsfor1h.(D)InhibitionofNFκB–luciferaseactivityinthestableHEK-293celllinewasdeterminedbypre-incubationofthecellswiththeindicatedconcentration
of compounds for 1 h followed by stimulation with 10ng/ml TNF-α in the continued presence of compound for a further 3 h. Results are means+ −S.E.M. from replicate determinations and are
representative of several independent experiments.
SUPPLEMENTARY EXPERIMENTAL
Protease selectivity assays
Protease selectivity of the compounds was assessed using a
panel of puriﬁed human enzymes (all from Calbiochem, EMD
Chemicals) by monitoring hydrolysis rates of peptide-AMC
substrates (all from Bachem) using ﬂuorescence measurements
as described for ‘In vitro assays of puriﬁed 20S’ in the main
paper, with modiﬁcations as follows. To measure the activities
of coagulation Factor β-XIIa (200 nM), chymotrypsin (2 nM),
elastase (4 nM), plasmin (4 nM), thrombin (4 nM), tissue
plaminogen activator (25 nM) and trypsin (4 nM) (ﬁnal
concentrations), reactions were performed at 30◦Ci n5 0 μl
of buffer containing 50 mM Tris/HCl, pH 8.0, 100 mM NaCl,
5m MC a C l 2,0 . 0 1 % Tween 20 and their respective substrates
Boc-QGR-AMC (50 μM), Suc-AAPF-AMC (40 μM), MeOSuc-
AAPV-AMC (50 μM), H-AFK-AMC (65 μM), Bz-FVR-AMC
(20 μM), Boc-E(OBzl)GR-AMC (50 μM) and Z-FR-
AMC (12 μM). The activities of cathepsin B and L were
measured using 2 nM enzyme in 50 μl of 100 mM sodium
acetate, pH 5.5, containing 5 mM DTT (dithiothreitol), 1 mM
EDTA, 0.01% Brij 35 and the respective substrates Z-RR-AMC
(60 μM) and Z-FR-AMC (37.5 μM). Calpain I activity was
measured using 200 nM enzyme in 50 μl of 50 mM Tris/HCl,
pH 7.4, containing 75 μMC a C l 2, 1.5 mM DTT and 100 μM
Suc-LY-AMC. Percentage inhibition of the proteases was
1 Present address: Epizyme, Inc., 840 Memorial Drive, Cambridge, MA 02139, U.S.A.
2 To whom correspondence should be addressed (e-mail jonathan.blank@mpi.com).
The structural co-ordinates of the yeast 20S proteasome with the indicated ligand bound reported will appear in the PDB under accession codes: 3MG0
(bortezomib); 3MG4 (compound 1); 3MG6 (compound 6); 3MG7 (compound 8); 3MG8 (compound 16).
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calculated relative to DMSO and either 2–20 μME 6 4[ trans-
epoxysuccinyl-L-leucylamido(4-guanadino)butane; Sigma] for
the cysteine proteases (cathepsins and calpain) or complete
EDTA-free protease inhibitor cocktail (1 tablet/ml diluted 1:10
(v/v) in assay buffer, Roche) for the remaining serine proteases.
Protein turnover assay
BulkproteinturnoverwasmeasuredinHCT-116cellsasdescribed
previously [1]. Brieﬂy, HCT116 cells (100000 cells/well in 12-
wellplates)werelabelledfor20 minundercellcultureincubation
conditions in methionine- and cysteine-free DMEM (Dulbecco’s
modiﬁed Eagle’s medium; Invitrogen), supplemented with 10%
dialysed FBS (fetal bovine serum), 2 mM L-glutamine and
50 μCi/well of EasyTag
TM EXPESS
35S-labelled methion-
ine/cysteine mix (NEN Radiochemicals, PerkinElmer). The cells
were then washed three times with the same medium containing
the unlabelled 2 mM methionine and 0.2 mM cysteine, and then
incubated with 3 μM compound in this medium for the indicated
times. Medium (50 μl) was removed from the cells and subjected
to liquid scintillation counting to monitor the release of
35S-
labelledpeptides.Attheendoftheexperiment,cellswerewashed
inPBS andthensolubilized in1 ml of0.2 MNaOHandsubjected
to liquid scintillation counting. Percentage protein turnover at
each time point was calculated as: [(total counts released into
medium)/(total counts released into medium+total counts in
NaOH-solubilized cells)]×100.
Synthesis of compound 1, the capped tri-peptide 5-methyl-N-((S)-
1-((S)-1-((S)-1-(4-methylbenzylamino)-1-oxo-4-phenylbutan-
2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)-1-oxo-4-phenylbutan-
2-yl)pyrazine-2-carboxamide
To a mixture of (S)-2-(tert-butoxycarbonylamino)-4-phenyl-
butanoic acid (0.634 g, 2.26 mmol) and 4-methylbenzylamine
(0.306 ml, 2.40 mmol) in dichloromethane (10.0 ml) was
added HBTU (O-benzotriazole-N,N,N
 ,N
 -tetramethyluronium-
hexaﬂuorophosphate) (0.984g, 2.6 mmol) and N-methylmor-
pholine (0.50 ml, 4.54 mmol). The reaction mixture was
stirred at room temperature overnight and then washed with
saturated aqueous NaHCO3. The organic layer was dried over
anhydrous MgSO4 and evaporated and the residue dissolved in
tetrahydrofuran (20 ml), treated with 4.0 M HCl in 1,4-dioxane
(20 ml) and stirred for 16 h at ambient temperature. The solvents
were removed in vacuo to give (S)-2-amino-N-(4-methylbenzyl)-
4-phenylbutanamide hydrochloride as an oil (0.70 g, 98%).
ESI (electrospray ionization)–MS +: calculated for C18H22N2O
[M+H] 283; found 283.
A solution of (S)-2-amino-N-(4-methylbenzyl)-4-phenylbu-
tanamide hydrochloride (0.50 g, 1.57 mmol) and (S)-2-(tert-
butoxycarbonylamino)-4-phenylbutanoic acid (0.439 g, 1.57
mmol)and2,4,6-collidine(0.571 mg,4.71mmol)inDMF(10 ml)
was treated with TBTU [O-(benzotriazol-1-yl)-N,N,N
 ,N
 -
tetramethyluronium tetraﬂuoroborate] (0.556 g, 1.73 mmol) and
stirred at ambient temperature for 3 h. The reaction mixture was
diluted with water and extracted with dichloromethane. The
extracts were dried over MgSO4 and evaporated. The residue
was re-dissolved in dichloromethane containing 1% MeOH
and hexane was added to precipitate tert-butyl (S)-1-[(S)-1-(4-
methylbenzylamino)-1-oxo-4-phenylbutan-2-ylamino]-1-oxo-4-
phenylbutan-2-ylcarbamate (0.546 g, 90%).
A solution of tert-butyl (S)-1-[(S)-1-(4-methylbenzylamino)-1-
oxo-4-phenylbutan-2-ylamino]-1-oxo-4-phenylbutan-2-ylcarba-
mate (0.754 g, 1.4 mmol) in dichloromethane (10 ml) was
FigureS2 Electrondensityofcompound6andthewatermoleculeinvolved
in peptide binding
A2 . 6A ˚ sigmaA-weighted Fo−Fc electron-density omit map contoured at 2.5σ covering
compound 6 and an associated water molecule in the β5/β6 active site of 20S is shown, with
positions P1–P4 indicated. After removal of all ligand atoms and water molecules from the
model, random co-ordinate displacements were added to remove model bias prior to several
cycles of reﬁnement and omit map calculation. For clarity, the portion of the omit map covering
the water molecule is coloured magenta and hydrogen bonds are indicated by dashed lines.
Atomsareshowninball-and-stickrepresentationwithcarboninyellow,nitrogeninblue,oxygen
in red, and sulfur in orange. The side-chain atoms for Asp114 (β6) are shown in ball-and-stick
representationcolouredasabove,exceptforcarboningreen.Proteinatomsfrom20Sareshown
in cartoon representation coloured by secondary structure with helices in cyan, β-strands in
magenta and loops in salmon. The ﬁgure was made using the PyMOL Molecular Graphics
System (DeLano Scientiﬁc, Palo Alto, CA, U.S.A.).
Figure S3 Comparison of the structures of compounds 8 and 6 bound to the
chymotrypsin-like site of the 20S proteasome
Close-up view of the S1 sub-pocket being ﬁlled by the ortho-chloro substituent in P1
for compound 8 (left-hand panel), compared with compound 6 that lacks this substituent
(right-handpanel). The colour scheme is as described in Figure S2.
treated with 4 M HCl in dioxane (2.1 ml, 10.4 mmol) and
stirred at room temperature for 4 h. The solvent was evaporated
and the residue triturated with ether to give the corresponding
amine hydrochloride (0.65 g, 100%) which was used without
further puriﬁcation. The next S-homo-Phe residue was coupled
as described for the previous step and the Boc protecting
group removed as described above to give (S)-2-amino-
N-{(S)-1-[(S)-1-(4-methylbenzylamino)-1-oxo-4-phenylbutan-
2-ylamino]-1-oxo-4-phenylbutan-2-yl}-4-phenylbutanamide as
the hydrochloride salt (81% yield). The amine described above
was coupled to 5-methylpyrazine-2-carboxylic acid using the
coupling conditions described above and worked up in the usual
way. The crude product was puriﬁed by ﬂash chromatography
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Figure S4 Correlation between in vitro and cellular potencies of bortezomib and compounds 1–16
Data presented in Tables 1 and 3 in the main paper are expressed in μM concentrations and compared to show the correlation between in vitro potency of the compounds against the β5 site of the
constitutive 20S proteasome determined with Ac-WLA-AMC as substrate and Calu6 cell Proteasome-GloTM β5I C 50, HEK293-NFκB-Luc IC50, MDA-MD-231-4xUb-Luc EC50 and Calu6 cell ATPlite
viability LC50. The viability effects of the compounds in Calu6 cells and H460 cells, as shown in Table 3 in the main paper, shown as LC50 values are expressed in μM concentrations and correlated.
The open symbol represents bortezomib and the closed symbols are numbered to indicate compounds 1–16.
on silica gel eluting with a gradient of 0 to 5% methanol in
dichloromethane to give 5-methyl-N-[(S)-1-{(S)-1-[(S)-1-(4-
methylbenzylamino)-1-oxo-4-phenylbutan-2-ylamino]-1-oxo-4-
phenylbutan-2-ylamino}-1-oxo-4-phenylbutan-2-yl]pyrazine-2-
carboxamide (compound 1) in 73% yield.
Compound 1
1H NMR (300 MHz, d6 DMSO) δ: 1.91 (m, 5H), 2.10 (m, 2H),
2.21 (s, 3H), 2.59 (m, 8H), 3.31 (s, 1H), 4.19 (m, 2H), 4.25 (m,
1H), 4.66 (m, 1H), 7.01 (d, 2H, J =7.8 Hz), 7.17 (m, 17H), 8.21
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Figure S5 Effect on intracellular protein turnover of potent di-peptide
proteasome inhibitors 11 and 16 compared with bortezomib
HCT116 cells were metabolically labelled for 20 min with [35S]methionine/cysteine and then
chased with excess unlabelled amino acids in the presence of compound 11, 16 or bortezomib
(each at 3μM) for the times indicated. Intracellular degradation of 35S-labelled proteins was
then determined as described in the Experimental section in the main paper and expressed as a
percentageoftotallabelincorporatedintotheproteins.Theresultsaremeans+ −S.E.M. (n=6)
and are representative of two similarly performed experiments.
(d, 1H, J =7.9 Hz), 8.34 (d, 1H, J =7.1 Hz), 8.45 (d, 1H, J =7.8
Hz), 8.65 (m, 1H), 8.81 (d, 1H, J =8.3 Hz), and 9.05 (d, 1H,
J =11.6 Hz). HRMS (high-resolution MS; ESI+): calculated
for C44H48N6O4 [M+H] 725.3815; found 725.3799.
Synthesis of (S)-2-(tert-butoxycarbonylamino)-4-
(neopentylamino)-4-oxobutanoic acid (compound 18)
Compound 18 was prepared according to Scheme S1. A solution
of Boc-Asp-OBn (0.937g, 2.9 mmol), neopentylamine (0.267 g,
2.9 mmol), HBTU (O-benzotriazole-N,N,N
 ,N
 -tetramethyl-
uronium-hexaﬂuorophosphate) (1.33 g, 3.5 mmol) and
N-methylmorpholine (0.44 g, 4.4 mmol) in anhydrous methylene
chloride (15.0 ml) was stirred at ambient temperature for 16 h.
The solvent was evaporated and the residue obtained was
partitioned between ethyl acetate (35 ml) and saturated aqueous
NaHCO3 (25 ml). The organic layer was dried over anhydrous
MgSO4, concentrated and puriﬁed by ﬂash chromatography on
silica gel to afford (S)-benzyl 2-(tert-butoxycarbonylamino)-4-
(neopentylamino)-4-oxobutanoate (17) as a white solid (0.84 g,
96%) which was dissolved in methanol (3 ml) and stirred under
20 psi (1 psi=6.9 kPa) H2 for 2 h in the presence of 10%
palladium on carbon (10 mol%). The Pd/C was removed via
ﬁltration through celite and the solvent evaporated to afford 18 in
quantitative yield.
Compound 18
1H NMR (400 MHz, C
2HCl3) δ 6.59 (s, 1H), 5.90 (d, J =5.2 Hz,
1H), 4.41–4.27 (m, 1H), 3.48 (s, 1H), 3.22 (dd, J =13.3, 7.1 Hz,
1H), 3.02–2.94 (m, 2H), 2.76 (dd, J =15.6, 9.0 Hz, 1H), 1.44
Figure S6 Common occupancy of the chymotrypsin-like site of the 20S
proteasome by compounds 1, 6, 8 and 16
Superposition of the structures of compounds 1, 6, 8, and 16 bound to the β5/β6 active site of
20S,showingthemolecularsurfaceof20SwithpositionsP1–P4indicated.Thecolourscheme
is as described in Figure S2.
(s, 9H), 0.91 (s, 9H). MS (ESI+): calculated for C14H26N2O5
[M+H] 303; found 303.
Synthesis of capped di-peptide proteasome inhibitors
Arepresentativeprocedurefortheparallelsynthesisofcompound
arrays (denoted IV in Scheme 2 in the main paper) follows: a
deep-well polypropylene synthesis plate was charged with the
appropriate amine salts II (0.25 mmol) in one dimension and
a solution of the amino acid (0.25 mmol) constituting the P3
coupling partner in DMF (2.0 ml) added in the second dimension
by use of a Tecan liquid handler. HBTU (0.5 ml, 0.5 M solution
in DMF) and N-methylmorpholine (0.9 mmol) were then added
to each well by means of the liquid handler. The plate was shaken
at room temperature for 16 h. The residue in each well obtained
after evaporation of the solvent in a Genevac was partitioned
between CHCl3/THF (3:1) (3 ml per well) and saturated aqueous
NaHCO3 (2 ml)witheachsolutiondeliveredbytheliquidhandler.
The phases were separated by centrifugation and the aqueous
layer was extracted with additional CHCl3/THF (3:1) (3 ml) and
the combined organic layers were evaporated. The residue thus
obtained was treated with 4 M HCl in dioxane (2 ml), shaken
at ambient temperature for 5 h and concentrated in a Genevac
evaporator to remove solvent and residual HCl. The N-terminal
cap was then coupled and the ﬁnal products isolated as in the
Scheme S1 Synthesis of compound 18
(i) Neopentyl amine, HBTU, NMM, DCM, 25◦C, 24h; (ii) H2, Pd/C, MeOH.
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Figure S7 Sequence alignment of the human β5 subunits of the constitutive and immunoproteasome
PSB5_HUMAN (PSMB5, β5 constitutive subunit, upper sequence) is compared with PSB8_HUMAN (PSMB8, β5 immunoproteasome subunit, lower sequence), with regions of sequence identity
shaded black. Residues forming the inhibitor-binding pockets are indicated by circles below the aligned sequences and coloured as follows: S1 pocket in blue, S2 pocket in magenta and S3 pocket
in green. Note that Ala49 sits between the S1 and S3 pockets and has been assigned to both. Residues from the β6 subunit that form the S4 pocket, as well as a portion of the S3 pocket, are not
shown because this subunit does not differ between the constitutive and immunoproteasome.
Figure S8 Residue conservation between the β5/β6 active site of the
constitutive and immunoproteasome
Surface representation of the β5 (light blue) and β6 (grey) subunits of bovine 20S
proteasome (PDB entry 1IRU [56]). Residues that are non-identical between constitutive and
immunoproteasome are coloured red. The structure of compound 1 has been modelled into the
active site on the basis of a superposition of the β5 subunit structure from yeast 20S, reported
in the present study, with the corresponding subunit of the bovine 20S structure.
previous step. All ﬁnal compounds IV (some 1500 in total) were
puriﬁed by preparative reverse phase HPLC using mass-directed
fraction collection and their purities and identities established
by LC-MS. Preparative HPLC was conducted on an Agilent 1100
seriesLC/MSDinstrumentusingaWatersSunFireC185 μmPrep
OBD column (19 mm×150 mm). The compounds were eluted
with a water–MeCN gradient (0.1% formic acid) optimized by
the A2Prep Agilent software. Compounds 2–16 described herein
were further characterized by 1H NMR spectroscopy and HRMS
(see below).
HRMS
Molecular mass measurements were performed using a QSTAR®
XL quadrupole TOF (time-of-ﬂight) mass spectrometer (Applied
Biosystems) coupled to an 1100 series HPLC system (Agilent
Technologies). An isocratic ﬂow of 50% solvent A (20%
CH3CN/80% H2O with 0.1% CH3COOH) and 50% solvent
B (100% CH3CN with 0.1% CH3COOH) at 200 μl/min was
used to deliver each sample to the electrospray source of the
mass spectrometer, tuned in ESI TOF-MS positive mode with a
3 min acquisition time for each analysis. The mass spectrometer
was externally calibrated between m/z 400 and 800 by using API
Calibration (NaCsI) Solution (Waters Corp). For each analysis,
approx. 5 scans were summed and the centroid m/z value of the
protonated monoisotopic molecular ion [M+H]
+ was recorded.
The relative deviations from the calculated exact masses based on
the expected formulae were also calculated. For each compound,
the experimental and calculated [M+H] values were within + −4
ppm, supporting their expected elemental composition (see the
Supplementary Results section).
SUPPLEMENTARY RESULTS
1H NMR and HRMS data for synthetic compounds
Compound 2
1H NMR (400 MHz, d6 DMSO) δ: 1.82 (m, 2H), 1.92 (m, 2H),
2.22 (s, 3H), 2.56 (m, 2H), 3.45 (d, 1H), 3.55 (d, 1H), 4.20 (d,
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Table S1 Crystallographic data and reﬁnement statistics
rmsd, root mean square deviation.
Compound
B o r t e z o m i b 1681 6
PDB ID 3MG0 3MG4 3MG6 3MG7 3MG8
Space group P21 P21 P21 P21 P21
Unit cell dimensions (A ˚, ◦)a =136.1, b=300.5, c=145.8, β=113.2 134.6, 300.8, 144.7, 112.7 137.3, 299.6, 145.8, 113.7 136.0, 300.4, 145.8, 113.7 136.3, 299.2, 145.7, 113.1
Wavelength (A ˚) 0.97947 0.97931 0.97958 0.97958 0.97969
Resolution (A ˚) 50 - 2.7 50 - 3.1 50 - 2.6 50 - 2.8 50 - 2.6
Rsym* (%) 9.8 (32.8)† 11.6 (30.5) 9.2 (35.3) 12.3 (44.2) 7.3 (32.7)
Total observations 1017555 723147 2255995 950351 1034821
Unique reﬂections 276539 177491 315914 257519 315407
Average redundancy 3.7 4.1 7.1 3.7 3.3
<I/σ> 9.7 (2.5) 7.1 (2.8) 11.1 (2.7) 8.0 (2.2) 11.1 (2.9)
Completeness (%) 92.9 (71.6) 94.1 (61.2) 96.3 (76.9) 97.2 (85.7) 95.6 (85.9)
Reﬁnement resolution (A ˚) 50 - 2.7 50 - 3.1 50 - 2.6 50 - 2.8 50 - 2.6
Reﬂections (working/test) 272720/2818 173803/3565 310987/3189 251281/5191 308947/6368
Rcryst/Rfree (%)‡ 22.6/25.3 20.5/25.2 21.5/24.9 21.7/25.9 22.4/25.3
Protein atoms 49541 49541 49298 49298 49298
Ligand atoms 168 90 86 88 92
M e s a t o m s 0 2 42 42 42 4
Mg2+ atoms 0 10 10 10 10
Water atoms 1037 0 858 4 5
rmsd bond lengths (A ˚) 0.008 0.008 0.011 0.008 0.008
rmsd bond angles (◦) 1.11 1.13 1.31 1.14 1.12
Ramachandran analysis
Most-favoured (%/number) 88.5/4896 89.8/4969 90.4/4997 90.5/4993 91.3/5041
Additional allowable (%/number) 10.7/594 9.5/526 8.9/491 8.6/475 8.1/445
Generously allowed (%/number) 0.5/29 0.5/27 0.4/23 0.6/31 0.4/21
Disallowed (%/number) 0.3/14 0.2/13 0.3/16 0.3/16 0.2/13
*Rsym =( hkl i|Ii(hkl)−<I(hkl)>|)/ hkl iIi(hkl) for n independent reﬂections and i observations of a given reﬂection. <I(hkl)> is the average intensity of the ith observation.
†Numbers in parenthesis are for highest resolution shell.
‡Rcryst = h||Fo(h)|−|Fc(h)||/ h|Fo(h)|, where Fo and Fc are the observed and calculated structure factors respectively.
2H), 4.28 (m, 3H), 6.84 (m, 1H), 6.96 (m, 2H), 7.01 (m, 3H), 7.10
(m, 8H), 7.17 (m, 2H), 7.25 (m, 5H), 7.33 (m, 3H), 8.16 (d, 1H,
J =6.7 Hz), 8.32 (t, 1H, J =6.1 Hz), and 8.40 (d, 1H, J =8H z ) .
HRMS (ESI+): calculated for C42H43N3O4 [M+H] 654.3332;
found 654.3346.
Compound 3
1H NMR (300 MHz, d6 DMSO) δ: 2.25 (s, 3H), 2.67 (m, 1H),
2.90 (m, 1H), 3.01 (m, 1H), 3.12 (m, 1H), 3.42 (m, 2H), 3.65
(s, 3H), 3.67 (s, 3H), 4.18 (m, 2H), 4.51 (m, 1H), 4.57 (m, 1H),
6.65 (m, 1H), 6.71 (m, 1H), 6.81 (m, 4H), 6.97 (m, 5H), 7.05 (d,
3H, J =8.3 Hz), 7.12 (m, 2H), 7.20 (t, 2H, J =7.8 Hz), 7.35 (m,
4H), 7.59 (d, 1H, J =7.7 Hz), 8.19 (d,d, 1H, J =14.0, 7.9 Hz),
and 8.33 (m, 1H). HRMS (ESI+): calculated for C44H44N4O6
[M+H] 725.3339; found 725.3336.
Compound 4
1H NMR (400 MHz, d6 DMSO) δ: 0.99 (d, 3H, J =6.3 Hz), 1.83
(m, 1H), 1.98 (m, 1H), 2.25 (s, 3H), 2.57 (m, 2H), 3.56 (d, 1H,
J =14.1 Hz), 3.60 (d, 1H, J =13.8 Hz), 4.00 (m, 1H), 4.22 (m,
4H), 5.05 (d, 1H, J =5.1 Hz), 6.84 (m, 1H), 6.98 (m, 3H), 7.12
(m,9H),7.27(m,3H),7.36(m,2H),8.03(d,1H,J =8.1Hz),8.10
(d, 1H, J =8.3 Hz), and 8.36 (t, 1H, J =5.9 Hz). HRMS (ESI+):
calculated for C33H39N3O5 [M+H] 594.2968; found 594.2981.
Compound 5
1H NMR (400 MHz, DMSO) δ 8.32 (t, J =6.0 Hz, 1H), 8.15 (d,
J =8.0 Hz, 1H), 7.98 (d, J =8.0 Hz, 1H), 7.86 (d, J =8.9 Hz,
2H), 7.43–7.36 (m, 4H), 7.24 (t, J =7.3 Hz, 2H), 7.19–7.03 (m,
9H), 5.14 (s, 2H), 5.02 (d, J =6.5 Hz, 1H), 4.42 (dd, J =8.0, 4.9
Hz, 1H), 4.30 (td, J =8.7, 4.8 Hz, 1H), 4.20 (dt, J =12.5, 6.2 Hz,
2H), 4.11 (dd, J =11.5, 6.3 Hz, 1H), 2.65–2.52 (m, 2H), 2.25 (s,
3H), 2.03–1.93 (m, 1H), 1.92–1.75 (m, 1H), 1.27 (s, 9H), 1.12
(d, J =6.3 Hz, 3H). HRMS (ESI+): calculated for C40H47N3O5
[M+H] 650.3596; found 650.3594.
Compound 6
1H NMR (400 MHz, DMSO) δ 8.38 (dt, J =11.9, 6.0 Hz, 1H),
8.03(dd,J =8.1,3.8Hz,2H),7.53(dd,J =8.5,2.6Hz,1H),7.26
(dd, J =10.1, 4.8 Hz, 2H), 7.21–7.04 (m, 8H), 6.96 (dd, J =8.5,
2.0 Hz, 1H), 5.03 (s, 1H), 4.34 (dd, J =8.1, 4.5 Hz, 1H), 4.29
(td, J =8.6, 4.7 Hz, 1H), 4.22 (dd, J =5.5, 2.8 Hz, 2H), 4.03 (dd,
J =6.3, 4.7 Hz, 1H), 3.84 (d, J =2.2 Hz, 3H), 3.69–3.59 (m, 1H),
2.85(dd,J =14.3,5.1Hz,1H),2.76–2.67(m,1H),2.65–2.51(m,
2H), 2.46–2.35 (m, 2H), 2.24 (s, 3H), 2.06–1.93 (m, 1H), 1.90–
1.78 (m, 1H), 1.06 (d, J =6.3 Hz, 2H), 1.00 (d, J =6.3 Hz, 1H).
HRMS (ESI+): calculated for C34H39N3O6 [M+H] 586.2917;
found 586.2931.
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Table S2 Protease selectivity of compounds
Protease selectivity of compounds was assessed using ﬂuorigenic peptide-AMC substrates and a panel of puriﬁed human enzymes, as described in the Supplementary Experimental section.
Percentage inhibition of the proteases was determined in the presence of 100μM compound and calculated relative to DMSO and the inhibitor control E64 or complete EDTA-free protease inhibitor
cocktail. Results are means obtained from two independent experiments, each performed in duplicate.
Enzyme inhibition at 100μM compound (%)
Compound Cathepsin B Cathepsin L Coagulation Factor β-XIIa Chymotrypsin Elastase Plasmin Thrombin Tissue plasminogen activator Trypsin Calpain I
1 −15 12 45 −4 −8 −20 22 21 12 −9
21 55 3 7 −3 −6 −12 12 14 0 17
3 1 22 34 1 −7 −15 21 16 −1 −12
4 −31 6 3 8 1 −3 −91 7 1 9 3 2 9
52 04 3 6 −8 −11 −18 12 12 −25
63 3 2 6 8 4 1 −11 12 12 −68
72 0 −93 1 3 0 −12 21 14 2 −11
8 −33 3 3 6 9 −1 −11 29 18 1 55
9 −14 3 34 −4 −6 −13 13 13 3 25
10 −13 18 32 2 −5 −18 13 13 −12 2
11 17 −64 0 3 6 −4 5 30 26 15 −40
12 −72 1 3 8 2 1 2 −11 5 1 7 2 7
13 −62 8 3 3 0 1 −10 12 17 −25 0
14 −80 3 5 −10 −10 −18 9 8 −41 5
15 −67 4 2 −42 −15 15 12 1 32
16 10 −34 9 2 3 1 4 1 1 3 43 4 2 0 6
TableS3 Anti-proliferativeeffectsofcompound1andbortezomibincancer
cell lines
Theindicatedcelllines(1000–2000cellsperwell)wereincubatedwitharangeofconcentrations
of compound 1 or bortezomib for 72h under cell culture conditions. Cell viability was
assessed my monitoring cellular ATP levels using the luminescence-based ATPlite assay as
describedintheExperimentalsectionofthemainpaper.IC50 dataaremeans+ −S.E.M.for3–11
determinations.
ATPlite cell viability LC50 (nM)
Cell line Compound 1 Bortezomib
MDA-MB-231 150+ −23 8.6+ −1.0
Calu6 130+ −10 5.2+ −0.76
H460 380+ −110 13+ −2.0
HCT116 50+ −8.1 4.6+ −0.68
HT29 55+ −8.9 5.4+ −1.1
Compound 7
1H NMR (400 MHz, d6 DMSO) δ: 1.12 (d, 3H, J =6.3 Hz), 1.90
(m, 2H), 2.60 (m, 2H), 2.75 (s, 1H), 2.84 (s, 2H), 4.09 (m, 1H),
4.48 (m, 3H), 4.78 (d, 1H, J =6.4 Hz), 4.91 (m, 1H), 5.19 (s,
2H), 7.20 (m, 11H), 7.33 (t, 2H, J =7.4 Hz), 7.40 (t, 2H, J =6.1
Hz), 7.47 (d, 2H, J =7 Hz), 7.89 (m, 2H), 7.97 (m, 1H), and
8.29(m,1H).HRMS(ESI+):calculatedforC36H39N3O5 [M+H]
594.2968; found 594.2967.
Compound 8
1H NMR (300 MHz, d6 DMSO) δ: 1.12 (d, 3H, J =6.3 Hz), 1.89
(m, 1H), 2.01 (m, 1H), 2.63 (m, 2H), 3.31 (s, 1H), 4.13 (m, 1H),
4.38 (m, 2H), 4.43 (m, 1H), 5.00 (d, 1H, J =6.5 Hz), 5.19 (s,
2H), 7.10 (d, 2H, J =9.1 Hz), 7.16 (m, 3H), 7.36 (m, 11H), 7.87
(d, 2H, J =8.98 Hz), 7.99 (d, 1H, J =8 Hz), 8.22 (d, 1H, J =8
Hz), and 8.39 (t, 1H, J =5.9 Hz). HRMS (ESI+): calculated for
C35H36ClN3O5 [M+H] 614.2422; found 614.2404.
Compound 9
1HNMR(400MHz,d6DMSO)δ:0.78(s,9H),1.83(m,1H),2.01
(m, 1H), 2.25 (s, 3H), 2.72 (m, 5H), 4.21 (m, 3H), 4.76 (d, 1H),
5.17 (s, 2H), 7.16 (m, 11H), 7.39 (m, 6H), 7.84 (m, 3H), 8.21 (d,
1H, J =8.1 Hz), 8.42 (m, 1H), and 8.53 (d, 1H). HRMS (ESI+):
calculated for C41H48N4O5 [M+H] 677.3703; found 677.3729.
Compound 10
1H NMR (400 MHz, d6 DMSO) δ: 0.78 (s, 9H), 1.82 (m, 1H),
2.03 (m, 1H), 2.24 (s, 3H), 2.44 (m, 3H), 2.63 (m, 3H), 2.80 (m,
4H), 4.14 (m, 2H), 4.25 (m, 1H), 4.60 (m, 1H), 6.98 (m, 3H), 7.11
(m, 7H), 7.25 (m, 3H), 7.85 (t, 1H, J =6.1 Hz), 8.22 (d,d, 2H,
J =5.4, 7.7 Hz), and 8.45 (t, 1H, J =6.1 Hz). HRMS (ESI+):
calculated for C36H45FN4O4 [M+H] 617.3503; found 617.3527.
Compound 11
1H NMR (400 MHz, d6 DMSO) δ: 0.75 (s, 9H), 1.25 (d, 3H,
J =7.4 Hz), 2.71 (m, 2H), 2.80 (d, 2H, J =6.2 Hz), 4.27 (m, 3H),
4.67 (m, 1H), 7.02 (m, 1H), 7.19 (m, 1H), 7.26 (m, 2H), 7.35 (m,
1H), 7.53 (m, 1H), 7.89 (t, 1H, J =6.3 Hz), 8.22 (m, 1H), 8.32
(d, 1H, J =7.3 Hz), 8.46 (t, 1H, J =6.1 Hz), 8.71 (d, 1H, J =8.1
Hz), 8.75 (s, 1H), and 12.25 (s, 1H). HRMS (ESI+): calculated
for C29H33F2N5O5 [M+H] 570.2528; found 570.2510.
Compound 12
1H NMR (400 MHz, d6 DMSO) δ: 0.75 (s, 9H), 1.27 (d, 3H,
J =6.9 Hz), 2.41 (m, 3H), 2.71 (m, 5H), 4.24 (t, 1H, J =7.4 Hz),
4.32 (m, 2H), 4.58 (d, 1H, J =6.8 Hz), 7.18 (m, 3H), 7.27 (m,
5H), 7.41 (m, 1H), 7.84 (t, 1H, J =5.7 Hz), 8.14 (d, 1H, J =8.1
Hz),8.33(d,1H,J =6.9Hz),and8.51(t,1H,J =5.3Hz).HRMS
(ESI+): calculated for C28H37ClN4O4 [M+H] 529.2582; found
529.2602.
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Compound 13
1H NMR (400 MHz, d6 DMSO) δ: 0.75 (s, 9H), 2.36 (m, 4H),
2.56 (m, 1H), 2.74 (m, 3H), 2.89 (m, 1H), 3.18 (m, 1H), 4.35 (m,
2H), 4.54 (m, 2H), 7.17 (d, 3H, J =6.5 Hz), 7.28 (m, 6H), 7.42
(m,1H),7.72(d,1H,J =7.9Hz),7.84(t,1H,J =3.9Hz),8.08(d,
1H, J =7.7 Hz), 8.36 (d, 1H, J =7.9 Hz), 8.44 (m, 2H), and 8.60
(t, 1H, J =5.4 Hz). HRMS (ESI+): calculated for C33H40ClN5O4
[M+H] 606.2847; found 606.2866.
Compound 14
1H NMR (400 MHz, DMSO) δ 8.20 (d, J =7.8 Hz, 1H), 8.08
(d, J =7.9 Hz, 1H), 7.88 (dd, J =13.3, 7.2 Hz, 1H), 7.77 (d,
J =7.8 Hz, 1H), 7.22 (dd, J =13.2, 6.5 Hz, 4H), 7.13 (t, J =7.3
Hz, 6H), 4.55 (dd, J =14.2, 7.5 Hz, 1H), 4.05 (s, 1H), 3.80 (dd,
J =13.9, 6.5 Hz, 2H), 2.89–2.83 (m, 2H), 2.80–2.73 (m, 2H),
2.70 (t, J =2.7 Hz, 2H), 2.44–2.36 (m, 3H), 1.97 (s, 1H), 1.74 (s,
1H),1.02(dd,J =18.7,6.6Hz,6H),0.80(s,9H).HRMS(ESI+):
calculated for C31H44N4O4 [M+H] 537.3441; found 537.3442.
Compound 15
1H NMR (400 MHz, DMSO) δ 8.20 (dd, J =7.9, 3.2 Hz, 2H),
8.11 (t, J =5.7 Hz, 1H), 7.87 (t, J =6.2 Hz, 1H), 7.33–7.07 (m,
10H), 5.77 (ddt, J =17.2, 10.3, 5.1 Hz, 1H), 5.10 (dq, J =17.2,
1.7 Hz, 1H), 5.03–4.98 (m, 1H), 4.60 (dd, J =14.5, 7.4 Hz, 1H),
4.15–4.07(m,1H),3.67(dd,J =12.1,5.2Hz,2H),2.94–2.75(m,
4H), 2.69–2.57 (m, 2H), 2.56–2.51 (m, 2H), 2.42 (dd, J =9.2, 6.5
Hz, 2H), 2.08–1.96 (m, 1H), 1.90–1.72 (m, 1H), 0.81 (s, 9H).
HRMS (ESI+): calculated for C31H42N4O4 [M+H] 535.2384;
found 535.328.
Compound 16
1H NMR (300 MHz, d6 DMSO) δ: 0.74 (s, 9H), 2.66 (m, 2H),
2.79 (m, 2H), 2.91 (m, 1H), 3.10 (m, 1H), 4.34 (d, 2H, J =5.8
Hz), 4.64 (m, 2H), 7.27 (m, 7H), 7.42 (m, 1H), 7.54 (m, 1H), 7.87
(t, 1H, J =6.2 Hz), 8.23 (m, 1H), 8.37 (d, 2H, J =5.93 Hz), 8.44
(d, 1H, J =8.24 Hz), 8.62 (t, 1H, J =5.84 Hz), 8.72 (m, 2H),
and 12.26 (m, 1H). HRMS (ESI+): calculated for C34H37ClN6O5
[M+H] 645.2592; found 645.2586.
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